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Summary
Sepsis and septic shock exhibit a broad spectrum of immunological
disorders with a very heterogeneous clinical manifestation. The heterogeneity makes
understanding pathomechanisms extremely dicult, implicating therapeutic failures
and complicating the discovery of novel treatments.
To better understand the pathomechanisms the underlying heterogeneity is
required to be dealt with proper stratication. With an aim to improve the outcome
with corticosteroids and sex-steroids independently in critically ill patients, this
study employed clinico-transcriptomics approaches that implemented stratication
at either clinical or molecular levels followed by an investigation of
pathomechanisms using high throughput transcriptomic analyses.
In septic shock patients, corticosteroids treatment is one of the crucial
supportive therapies known to resolve the septic shock eectively. However,
large-scale clinical trials point towards ambiguous conclusions on the eect of
corticosteroids (mainly hydrocortisone) on the patient outcome. The critical task
remains on how to identify the subset of patients that can potentially benet from
the treatment. Addressing this issue, in this thesis, a blood serum ratio of IFN and
IL-10 was discovered as a promising new theranostic marker for the treatment of
hydrocortisone, and it was validated on three further independent datasets. A high
IFN/IL-10 ratio in patients indicated better recovery-cum-survival without
hydrocortisone treatment while a benet was observed for patients with low ratios
when hydrocortisone treatment was initiated. The recovery was seen regarding
reduced serum lactate and norepinephrine requirement levels over time.
Furthermore, ex vivo blood culture experiments indicated that the ratio negatively
associates with the pathogen load in spiked human blood in an `on-o' manner. The
pathomechanisms behind the recovery were then characterized using transcriptomics
data. High ratios indicated the upregulation of activation signatures of macrophages
and T-cells in the patients. Moreover, the immune recovery was observed when the
hydrocortisone treatment was initiated in patients with low ratios.
Much like the role of corticosteroids, a lack of consensus exists on the role of
sex-steroids during sepsis. Although modulation of sex-hormones has been proven
eective in experimental sepsis models, their usage is far away from clinics, mostly
because the literature lacks consensus on explaining the underlying sex-based
pathomechanisms. The lack of stratication approaches is apparent, and the
underlying heterogeneity seems to have contributed vastly to these studies. To
address the issue, in this thesis a statistical framework for stratication of
patient-severity was developed. Clinical and transcriptional data from a larger
longitudinal study of critically ill patients after trauma was investigated. The
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stratication enabled the identication of pre-acute, acute and post-acute phases of
the organ-dysfunction. During each phase, the gene sets explaining the sex-based
pathomechanisms in peripheral leukocytes were identied. The transcriptomic
proles revealed that after critical injury, pre-menopausal female and male patients
exhibited a distinctively dierent transcriptomic response. Before the most severe
day (i.e. the day with the highest Multiple-organ-failure score), female patients
showed dierential regulation for a stronger innate immune response, before and at
the most severe day better bioenergetic tolerance and better oxidative damage
resistance. They showed early upregulation of wound healing mechanisms and, after
the most severe day, a distinct upregulation of the adaptive immune system. These
observations were enabled due to the synchronization of patients' severity proles
before transcriptomic investigations.
The benets in pre-menopausal female patients were reported mostly to be due
to sex hormones. Animal studies conducted previously in the group have shown
that sex-hormone modulation by treating with Atraric acid or Flutamide improves
survival in male septic mice. These treatments are known to induce anti-androgenic
and pro-estrogenic regulation. To decipher the underlying pathomechanisms, the
transcriptomic response of the liver of septic mice to the sex-hormone modulation
was studied. The transcriptomics of the liver showed a regulatory shift in septic male
mice towards female upon treatment. Compared to septic males, liver of females
showed the properties of tolerance in which protection from antigenic overload is
gained by receptor desensitization, reduced immunoreactivity, and inhibition of cell
death. The female-like response of the treatments largely mimicked the tolerance
properties seen in females. The transcriptomics of female and female-like response of
the treatments support a strong possibility that the survival advantage could be from
enhanced tolerance as a defense strategy.
In summary, the clinico-transcriptomics approaches can serve as vital means in
overcoming therapeutic failures and aiding the discovery of novel treatments for
critically ill patients.
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Zusammenfassung
Sepsis und die haug damit zusammenhangende Folge der schweren Sepsis,
sowie der septische Schock beschreiben ein breites Spektrum an Storungen des
Immunsystems des Wirts, an der endogene Hormone mageblich beteiligt sind. Das
Ziel dieser Arbeit war es deshalb, den Einuss von Kortikosteroiden oder
Sexualhormonen, besser zu verstehen und durch die Behandlung mit diesen
Hormonen das Uberleben der Patienten zu verbessern.
Die Kortikosteroidtherapie von Patienten mit septischem Schock ist eine
wichtige supportive Manahme. Trotzdem zeigten diverse klinische Studien keinen
eindeutigen Eekt von Kortikosteroiden auf das Uberleben der Patienten. Die
Herausforderung hierbei ist es, die Patientensubpopulation zu denieren, die von
der Therapie protiert. Die vorliegende Arbeit identizierte den Quotienten der
gemessenen Zytokine IFN und IL-10 aus Blutserum als neuen und
vielversprechenden theranostischen Marker. Ein hohes IFN/IL-10-Verhaltnis im
Patientenblut korrelierte mit verbessertem Uberleben, sofern diese nicht mit
Kortikosteroiden behandelt wurden, wahrend Patienten mit einem niedrigen
IFN/IL-10-Quotienten von der Behandlung protierten, was sich in beiden Fallen
sowohl in den sinkenden Serum-Lakat-Werten als auch in der verringerten
Norepinephrin-Bedarf widerspiegelte. Die zugrundeliegenden Pathomechnismen der
besseren Genesung wurden mittels Trasnkriptomdaten charakerisiert und zeigten
bei einem hohen Verhaltnis eine Hochregulierung der Makrophagen- und
T-Zell-Aktivierung in den Patienten. In Patienten mit niedrigem Quotienten wurde
diese vorteilhafte Aktivierung der Immunzellen nur in den Patienten beobachtet, die
mit Hydrokortison behandelt wurden.
Ebenso kontrovers wie die Behandlung mit Kortikosteroiden wird die Rolle von
Sexualhormonen wahrend der Sepsis diskutiert. Obwohl die Modulation von
Sexualhormonen in Sepsis-Tiermodellen einen positiven Eekt zeigte, liegt deren
klinische Anwendung noch in weiter Ferne, vor allem da der zugrundeliegende
geschlechtsspezische Pathomechanismus und dessen Beeinussung bisher nicht
aufgeklart ist. Hierfur wurden klinische Parameter und Transkriptomdaten einer
groen longitudinalen Studie schwerkranker Traumapatienten untersucht. Die eigens
dafur in dieser Arbeit entwickelte zeitliche Stratizierung erlaubte die Identikation
markanter dierenzieller Pathways in der pra-akuten, akuten und post-akuten Phase
der Organdysfunktion, im Vergleich pra-menopausaler Frauen und Manner. Vor
dem schwerwiegendsten Krankheitstag (Tag mit dem hochsten Wert fur multiples
Organversagen, MOF-Score) wiesen die Frauen eine hohere Expression des
angeborenen Immunsystems auf und vor dem und am schwerwiegendsten
Krankheitstag auerdem eine hohere Expression von Genen fur bioenergetische
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Toleranz und oxidative Stressresistenz. Des Weiteren zeigten Frauen eine fruhe
Hochregulation von Wundheilungsmechansimen und nach dem schwerwiegendsten
Krankheitstag eine dierenzielle Erhohung des adaptiven Immunsystems.
Veroentlichungen verknupfen den vorteilhaften Verlauf bei pra-menopausalen
Frauen meistens mit den Sexualhormonen. Tierstudien bestatigten die Hypothese
der Modulation von Sexualhormonen zur Uberlebensverbesserung mannlicher
septischer Mause durch eine Kombination aus antiandrogener und proostrogener
Behandlung aufgrund der Gabe von Atrarsaure oder Flutamid. Zur Untersuchung
des Pathomechanismus wurden die Transkriptomdaten der Leber dieser septischen
Mause verglichen. Die Transkriptomprole der behandelten mannlichen Mause
zeigten eine Verschiebung zu den weiblichen Transkriptomprolen im Vergleich zu
den unbehandelten Mannchen. Die Weibchen zeigten eine erhohte Toleranz, die
durch den Schutz vor Antigenuberlastung mittels Rezeptordesensitisierung erreicht
wird, eine geringere Immunreaktivierung und geringeren Zelltod. Die
Weibchen-ahnlichen Transkriptomprole der behandelten Mannchen wiesen in
weiten Teilen eben diese Toleranz-Anzeichen auf. Diese Modulation konnte das
Uberleben der septischen mannlichen Mause aufgrund einer daraus resultierenden
erhohten Toleranz als Verteidigungsmechanismus verbessert haben.
Zusammenfassend ergaben sich ein neuer Ansatz zur Entscheidungsunterstutzung
von Kortikosteroidgabe bei septischem Schock und die Identizierung entscheidender
Unterschiede der Regulationsmuster von Mannern und Frauen bzw. mannlichen und
weiblichen Mausen in Immunzellen von Sepsis Patienten und Leberzellen in septischen
Mausen. Diese Ergebnisse werden dazu beitragen, Fehltherapien zu verhindern und
neue Behandlungen schwerkranker Patienten zu nden.
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Chapter 1
Introduction
1.1 Sepsis
Sepsis is one of the oldest and most complex diseases. Hippocrates in his journals
described sepsis as a process by which esh rots, swamps generate foul airs and wounds
fester [Majno, 1991]. Galen later considered sepsis a worthy and necessary step for
wound healing [Funk et al., 2009]. With the conrmation of germ theory by Bassi,
Pasteur, and others, sepsis was redened as a systemic infection, often described
as `blood poisoning', and assumed to be the consequence of the host's invasion by
pathogens that then spread in the bloodstream [Majno, 1991, Funk et al., 2009].
All these paradigms were not adequate since sepsis patients died despite successful
clearance of the initiating pathogen. Work over the past three decades has revealed
sepsis as a clinical syndrome or disease continuum of organ dysfunction [Gotts and
Matthay, 2016]. In addition to its initiation by pathogens, the host response to sepsis
is more focused, considering that this drives the pathogenesis [Marshall, 2014].
Our understanding of the pathophysiology of sepsis has evolved substantially
over the last three decades [Gotts and Matthay, 2016]. For many years, the
inammatory dynamics of sepsis have been incompletely explored. Early septic
deaths were presumed to be a consequence of exaggerated host's proinammatory
immune response [Bone, 1992]. Excess release of systemic cytokines such as tumor
necrosis factor (TNF), interleukin-6 (IL-6), and interleukin-1 (IL-1) was
well-documented in the septic human response and animal models. These ndings
drove the dominant concept of sepsis as a hyperinammatory state and
consequently resulted in many unsuccessful anti-inammatory studies [Angus, 2011].
Later a multimodal hypothesis of sepsis was proposed in which an initial systemic
inammatory response syndrome (SIRS) in sepsis was believed to be a temporary
2
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phenomenon followed by a compensatory anti-inammatory response syndrome
(CARS) often increasing the risk of secondary infections and other adverse
outcomes [Hotchkiss et al., 2016]. Subsequently, simultaneous production of
circulating proinammatory and anti-inammatory cytokines has been
demonstrated in a model of polymicrobial sepsis, supporting that a continuously,
highly mixed anti-inammatory response syndrome (MARS) is present [Osuchowski
et al., 2012]. Patient studies showed similar results and demonstrated that both
classes of cytokines have an integral role in sepsis from the onset and onwards
[Novotny et al., 2012]. Inadequate understanding of the pathophysiology has
created fundamental problems in tackling it and its related complications that
ultimately are leading to death.
Today, sepsis and septic shock are the most common causes of death among
critically ill patients in non-coronary intensive care units [Hotchkiss et al., 2016]. In
Germany, an approximate hospitality death rate for severe sepsis was reported to be
55% [Engel et al., 2007]. Case numbers of severe sepsis exceed 750,000 per year and
were considered to rise steadily in the United States [Angus et al., 2001, Lagu et al.,
2012]. A recent estimation made in 2015 for the worldwide population was more
than 31 million sepsis and 19 million severe sepsis cases per year [Fleischmann et al.,
2016]. Several factors contribute to sepsis susceptibility and outcome such as the
initial site of infection, causative microbe, the pattern of acute organ dysfunction,
co-morbidities of the patient and the amount of delay in initiation of antimicrobials
[Angus and van der Poll, 2013]. For example, hourly delays in the rst appropriate
antimicrobial administration were associated with higher mortality [Weiss et al.,
2014]. Unfortunately, identifying the infection imposes hurdles on detecting if the
patient has sepsis. Blood cultures, which is the standard diagnostic method for
microbe detection, are typically negative in more than half of the severe sepsis cases
[Dellinger et al., 2008].
Besides the recognition of sepsis, its treatment is the primary challenge for
clinicians. Despite many years of intensive research `sepsis drug' is yet to be found.
Therefore, sepsis was called as `graveyard for pharmaceutical companies'
[Riedemann et al., 2003]. The seemingly promising therapy with recombinant
activated protein C (drotrecogin alpha) was unfortunately removed from the market
in 2011 since it increased severe bleeding and ultimately did not decrease mortality
[Mart-Carvajal et al., 2007]. Activated protein C has pleiotropic biological eects
on the inammatory response and coagulation, and it was shown to be eective in
the preclinical animal models of sepsis in reducing organ damage and mortality
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[Mart-Carvajal et al., 2007]. Apart from this trial, there have been more than 100
randomized clinical trials testing strategies to modify the septic response to improve
survival but failed. These strategies included nonspecic suppression of
inammation using corticosteroids or ibuprofen; the specic blockade of microbial
products such as endotoxin or host inammatory mediators such as tumor necrosis
factor (TNF), interleukin-1 (IL-1), toll-like receptor 4 (TLR4), platelet-activating
factor, and nitric oxide; nonspecic targeting of inammatory mediators using
polyclonal immunoglobulins; the administration of immunity-enhancing protein,
including granulocyte colony-stimulating factor (G-CSF) and interferon gamma
(IFN-); and the administration of anticoagulant molecules such as tissue factor
pathway inhibitor (TFPI), anti-tissue factor antibodies, antithrombin, and
thrombomodulin [Marshall, 2014].
Due to the signicant impact of sepsis on global health, several initiatives were
taken to improve the survival of patients with sepsis. One such initiative is the
Surviving Sepsis Campaign (SSC) with an objective of reducing mortality from sepsis
by 25% [Dellinger et al., 2008]. Several strategies have been implemented to achieve
this goal, such as early goal-directed therapy towards infection, early use of broad-
spectrum antibiotics, support for failing organs and low tidal volume ventilation.
Although the sepsis mortality rate has subsequently decreased, the SSC goal is far
from being achieved [Dellinger et al., 2013]. Even though there is no common eective
therapy due to high variability among sepsis patients, general predispositions exist
and, these include age (higher in newborns and elderly), ethnic background (higher in
blacks compared to whites) and gender (higher in men compared to women) [Angus
et al., 2001, Mayr et al., 2010].
1.1.1 Gender dimorphism in sepsis
In a large study observing 681,730 trauma patients, female patients showed
signicantly fewer complications and 21% lower death rate compared to male patients,
despite the same average of injury severity scores (ISS) [Haider et al., 2009]. A recent
meta-analysis involving 19 studies with 140,328 trauma patients found less mortality,
shorter duration of hospitalization, and fewer complications in female patients [Liu
et al., 2015]. Consistent with these ndings, male gender was associated with a higher
risk of major infections and Multiple-Organ-Failure (MOF) following trauma [Oner
et al., 1999, Gannon et al., 2004, George et al., 2003]. Mostafa et al. [Mostafa
et al., 2002], Deitch et al. [Deitch et al., 2007] and Trentzsch et al. [Trentzsch
et al., 2014, Trentzsch et al., 2015] observed that premenopausal female patients are
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better protected from MOF and sepsis after critical trauma. In particular, Trentzsch
et al. analyzed 3,887 matched-pairs of male and female severe-trauma patients and
observed that premenopausal females develop signicantly less MOF despite matching
injury, i.e. a matched Abbreviated Injury Scale score (for the thorax, head, abdomen,
extremities), age and co-morbidities [Trentzsch et al., 2015].
It was also reported that female patients respond better to supportive
treatments. In a study observing a cohort of 4,106 trauma patients, premenopausal
women required less blood transfusion and showed lower serum lactate levels despite
more severe injuries [Deitch et al., 2007]. In another, prospective clinical study,
female patients required lower resuscitation volumes (12 L vs 8 L), less inotrope and
vasopressor support (36% vs 10%) and less intervention (42% vs 15%) based on the
Starling curve to maintain oxygen delivery in the heart compared to similarly
injured male patients. The authors concluded that female patients responded better
to standardized resuscitation compared to male patients [McKinley et al., 2002].
Besides these clinical dierences, male and female individuals dier fundamentally
in regulating immune response and metabolism. Female individuals elicit a more
robust innate and cell-mediated immune response, making them less prone to certain
infections, like hepatitis-B, tuberculosis, leptospirosis and more [Klein and Flanagan,
2016]. They develop a higher antibody response to vaccination providing a better
anti-infection response; however, they are more prone to autoimmune diseases [Klein
and Flanagan, 2016]. Regarding metabolic dierences, studies have shown that energy
metabolism diers between healthy male and female individuals. Female individuals
oxidize more lipids preferably over carbohydrates, and they utilize less glycogen from
skeletal muscles thereby producing less hepatic glucose [Tarnopolsky and Ruby, 2001].
Notably, muscle cells of female individuals have a signicantly lower capacity for
anaerobic glycolysis and aerobic oxidation [Green et al., 1984].
Critical trauma-hemorrhage can lead to immune dysfunction and metabolic
derangements. It is often followed by the onset of sepsis. The hyper inammation
during sepsis leads to tissue damage, which, in turn, evokes the concomitant release
of pro- and anti-inammatory cytokines, but can also suppress a variety of
cell-mediated immune responses leading to immunosuppression [Xiao et al., 2011].
Trauma-hemorrhage is also known to trigger hyperglycemia, increased fatty acid
oxidation, and decreased ATP production resulting from mitochondrial dysfunction
[Marik and Raghavan, 2004, Singer, 2014]. In summary, the immune and metabolic
responses are severely altered after trauma-hemorrhage. Hence, studying the
implications of gender is crucial to understand the underlying pathomechanisms of
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trauma-hemorrhage.
1.1.2 Therapeutic potential of sex-steroids
Experimental studies in septic animal models have demonstrated the
modulation of immune responses by sex-steroids. Overall, testosterone, the primary
male sex hormone appears to have anti-inammatory and immunosuppressive
eects. It promotes the synthesis of anti-inammatory cytokines such as IL-10 by
macrophages [D'Agostino et al., 1999], reducing NK cell activity and the synthesis
of pro-inammatory cytokines, such as TNF-, via inhibition of nuclear factor
kappa B (NFB) [Hou and Zheng, 1988, McKay and Cidlowski, 1999]. Testosterone
has also been associated with the decreased expression of toll-like receptor 4 (TLR4)
in macrophages which is involved in the activation of the innate immune system and
production of inammatory cytokines [Rettew et al., 2008].
In contrast, the dominant female hormone, estrogen appears to enhance
cell-mediated and humoral immune responses. It accelerates NK cell cytotoxicity, as
well as stimulates the production of pro-inammatory cytokines including TNF-,
IL-6 and IL-1 [Miller and Hunt, 1996, Sorachi et al., 1993] and inhibits the
synthesis of anti-inammatory cytokines such as IL-10 [Kahlke et al., 2000]. Also,
estrogens have been shown to increase survival and prevent apoptosis of immune
cells [Straub, 2007, Vegeto et al., 1999]. Elevated systemic levels of estradiol in
pre-estrus female mice played a pivotal role in post-trauma and hemorrhage
immunocompetence [Knoferl et al., 2002]. Furthermore, administration of
17-estradiol (E2) was associated with marginal improvement in the survival rates
in male septic mice [Knoferl et al., 2000]. A single dose of estradiol following
trauma-hemorrhage and resuscitation was shown to restore depressed immune
responses [Knoferl et al., 2001].
Several murine studies have shown depressed immune responses in males as well
as ovariectomized females following trauma-hemorrhage and sepsis
[Ananthakrishnan et al., 2005, Angele et al., 2000]. Interestingly, pretreatment of
female mice with 5a-dihydrotestosterone (DHT) prior to trauma-hemorrhage
resulted in depressed macrophage function and cell-mediated immune responses
[Angele et al., 1998]. Moreover, castration and depletion of male sex hormones prior
to trauma-hemorrhage resulted in enhanced immune responses [Angele et al.,
2001, Wichmann et al., 1996]. Furthermore, castrated male animals treated with
DHT resurfaced the depressed cell-mediated immune responses, whereas additional
administration of estradiol prevented the depression of immune responses [Angele
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et al., 1999, Angele et al., 2001].
To clarify whether testosterone by itself is responsible for the depression of
cell-mediated immune responses in male mice, studies were conducted in which
female mice were pretreated with DHT for two weeks before the induction of
trauma-hemorrhage [Angele et al., 1998]. The results showed that female mice that
had articially elevated plasma testosterone levels (comparable to males) displayed
similar depression of splenic and peritoneal macrophage function as in males [Angele
et al., 1998]. Furthermore, pretreatment of female mice with DHT suppressed the
release of Th1 lymphokines, IL-2 and IFN- by splenocytes following
trauma-hemorrhage to levels comparable to healthy male animals [Angele et al.,
1998].
Integrating the lessons from male and female sex-hormone modulation
experiments, in males, the simultaneous suppression of male hormonal response and
activation of female hormonal response has been reported to signicantly increase
survival following the induction of severe polymicrobial sepsis (PCI) [Roll, 2015].
Pre-estrus females showed signicantly increased survival while all septic male mice
died within 28 hours post-PCI induction. A clinically used prostate cancer agent,
Flutamide (Flu) and the novel natural compound Atraric acid (AA) extracted from
the fruit of the plant Sabal serrulate were used independently to treat males at time
points 0, 4, 8, and 16 hours following induction of polymicrobial sepsis. The results
displayed a signicant increase in the rate of survival for up to 20-25% (Figure 1.1
adapted from [Roll, 2015]). Flu and AA are androgen receptor (AR) antagonists;
moreover, Flu is an indirect activator of estrogen receptor (ER) through the
induction of aromatase enzyme, while AA is a more potent activator of ER [Roll,
2015]. These ndings indicated that the simultaneous inhibition of AR and the
activation of ER could induce stronger femalization in male mice upon treatment,
following the polymicrobial sepsis. To determine the supportive cause of enhanced
survival, clinical severity scores and cytokine levels (IL-6, IL-10, TNF-, MCP-1,
IFN-, IL-12p70) were measured in blood serum and in liver tissue at 10 hours
post-PCI, together with liver function parameters (Lactate dehydrogenase,
Creatinine, Aspartate transaminase, Bilirubin). However, no signicant tendency
was found associated with either the treated group or with the females. Perhaps,
transcriptomic investigations at this time-point may identify the possible regulatory
mechanisms.
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Figure 1.1: For induction of sepsis a 100% lethal doses (2 l/g body weight) of a pre-
adjusted (referred to male mouse survival) and microbiologically characterized human feces
batch was injected intraperitoneally. Treatment with the indicated compounds or solvent
(0.5% TWEEN80 in 0.9% NaCl) for female mice and male solvent control group at time
points 0, 4, 8 and 16 hours post-PCI induction was performed. Kaplan-Meyer survival
curve and statistical analyses (Mantel-Cox test) were performed with GraphPad PRISM5
and asterisks (*) indicate signicant changes compared to male solvent control (dark blue)
with a p-value <0.05. The curves demonstrate a total animal number of n=20 (except for
solvent group n=10) whereat experiment was performed twice for each group with n=10.
Pre-estrus females (red curve) survive sepsis far better compared to males (dark blue curve)
(p=0.0002). Flu treatment (light green curve) or AA treatment (dark green curve) led to
signicant enhanced septic male survival compared to solvent treated male group (dark blue
curve) (pFlu=0.032; pAA=0.021). Source [Roll, 2015]
1.2 Septic shock
A deadlier sequelae of sepsis is septic shock. The current sepsis denitions (i.e.
Sepsis-3) describe septic shock as a subset of sepsis in which underlying circulatory
and cellular metabolic abnormalities are profound enough to increase mortality
substantially [Singer et al., 2016]. Patients with septic shock can be identied with
persisting hypotension requiring vasopressors to maintain mean arterial pressure
(MAP) 65 mmHg and having a serum lactate level >2 mmol/L (18 mg/dL)
despite adequate volume resuscitation [Singer et al., 2016]. Norepinephrine is
favored as the rst-line vasopressor for septic shock in the Surviving Sepsis
Guidelines [Dellinger et al., 2013]. It increases mean arterial pressure primarily
through vasoconstriction, with little eect on heart rate, stroke volume, and cardiac
output [Dellinger et al., 2013]. Serum lactate is produced by anaerobic respiration
mainly because of the insucient circulation during septic shock. Both, serum
lactate level and the norepinephrine requirement reect the shock severity in
patients and are used for monitoring patients [Dellinger et al., 2013].
Early supportive therapy with uid resuscitation and vasopressors to restore
hemodynamics and reduce tissue hypoxia is decisive for the patient's outcome
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[Dellinger et al., 2013]. However, mortality rates for septic shock may reach 60%
even with early recognition and treatment [Fleischmann et al., 2016]. The limited
improvement in septic shock survival can be explained by the inability to
prospectively identify the patient subset that is most likely to benet or be harmed
from a specic therapy. We are becoming increasingly aware that the response to
therapy is crucial and precision medicine is already an important research topic for
acute illnesses and septic shock [Wong et al., 2015]. Using a digital messenger RNA
quantication platform that can generate gene expression data in about 8{12 hours;
Wong et al. could subclassify children with septic shock based on a 100-gene gene
expression signature into subclasses that have clinically relevant phenotypes [Wong
et al., 2015]. The class-dening genes corresponded to adaptive immunity and
glucocorticoid receptor signaling, thus raising the possibility of a theranostic
approach to pediatric septic shock.
Therapy options for septic shock patients are very limited. Among them,
treatment with corticosteroids is one of the promising supportive therapy, known to
eectively resolve the septic shock, while some patients were reported to develop
adverse secondary infections [Sprung et al., 2008]. More research is required for
identifying the patient subsets that are most likely to benet or can get harmed
from corticosteroids therapy during septic shock.
1.2.1 Therapeutic role of corticosteroids
In septic shock patients, treatment with corticosteroids, mainly hydrocortisone
(HC) has been consistently reported to help in faster shock resolution [Annane
et al., 2009, Venkatesh et al., 2018], whereas a survival benet with HC treatment
was demonstrated only in two French randomized controlled multicenter trials when
administered together with udrocortisone [Annane et al., 2002, Annane et al.,
2018]. Conicting results regarding the mortality endpoint were obtained in two
other multinational trials, ADRENAL [Venkatesh et al., 2018] and CORTICUS
[Sprung et al., 2008]. Possible explanations for this disparity included dierences in
the patient population with a two-fold higher risk of mortality in the French control
group (61%) compared to CORTICUS (31%), and an increase in secondary
infections, including new episodes of sepsis or septic shock recorded with
corticosteroid application in the CORTICUS trial. The concern about the side
eects of corticosteroids such as infections in patients with less severe septic shock
stipulated more restrictive recommendations by the Surviving Sepsis Campaign. HC
application is currently recommended for severe courses if patients do not respond
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to adequate vasopressor therapy and uid resuscitation [Dellinger et al.,
2008, Dellinger et al., 2013]. To evaluate the eects of hydrocortisone on the
balance between pro- and anti-inammation, a randomized controlled study
(\Crossover" study) was performed investigating immune eects of a three-day
treatment in patients with septic shock followed by three days placebo, or vice versa
(HC and placebo were \crossed over") [Keh et al., 2003].
The crossover study demonstrated that HC restored hemodynamic stability and
modulated the immune response to stress by means of antiinammation rather than
immunosuppression [Keh et al., 2003]. Another, larger randomized trial (VASST)
[Russell et al., 2008] hypothesized that low-dose vasopressin improves the therapy of
septic shock patients compared to norepinephrine (conventional catecholamine). As
the main result, low-dose vasopressin did not reduce 28-days mortality rate.
Notably, in the studied cohort, about 75% of patients were treated with
corticosteroids in addition to vasopressin or norepinephrine. Bentzer et al. followed
up investigating corticosteroid-treated versus non-treated (only vasopressin or
catecholamine vasopressors) patients. They identied a signature of three cytokines
(Interleukin-3, Interleukin-6 and C-C-motif-chemokine-4) suggesting a response to
corticosteroid treatment [Bentzer et al., 2016]. However, these results were based on
a study which was not randomized, blinded or protocolized according to
corticosteroids treatment, nor the signature was validated on another independent
dataset. Further, Bentzer et al. neither distinguished between vasopressor and
norepinephrine treatment, nor elaborated on how these three cytokines interact with
corticosteroid treatment.
Corticosteroids are widely known for their immune suppressing eects [Coutinho
and Chapman, 2011, Barnes, 2011], mediated by the glucocorticosteroid receptor
(GR) which represses the pro-inammatory acting transcription factors like AP-1 or
NFB [Baschant et al., 2013]. Nevertheless, increasing evidence indicates
corticosteroids and GR to be involved in the activation of pro-inammatory
processes. Indeed, corticosteroid treatment was shown to induce the expression of
innate immune-related genes, like TLRs in human mononuclear cells as well as
anti-inammatory genes, displaying the pivotal role of corticosteroids [Chinenov and
Rogatsky, 2007, Galon et al., 2002]. In primary macrophages, corticosteroids
induced a central component of the inammasome resulting in secretion of
pro-inammatory cytokines such as interleukin-6 [Busillo et al., 2011]. The immune
activating role of corticosteroids has been described as a response to acute stress
enhancing the peripheral immune response, whereas chronic corticosteroid exposure
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leads to immune-suppression [Dhabhar, 2002, Cruz-Topete and Cidlowski, 2015].
Hence the context and the biotype identication of patients is required for
supporting the HC treatment decision of patients with septic shock.
1.3 Clinico-transcriptomics approaches
Transcriptomic analyses have been successfully used for diagnostics,
identifying novel virulence factors, predicting antibiotic resistance and studying
host-pathogen interactions [Lowe et al., 2017, Leonor Fernandes Saraiva et al.,
2017]. It has also been used to investigate the gender dimorphism in the gene
regulatory response to trauma [van Vught et al., 2017, Lopez et al., 2016]. Vaught
et al. compared gene expression proles of septic and healthy male and septic and
healthy female individuals. Blood of septic patients was drawn at the day of
admission. They identied that ERK and MAPK signaling, leukocyte extravasation
signaling, PDGF signaling, and ephrin receptor signaling are specically upregulated
in males but not in females [van Vught et al., 2017]. However, this indirect way of
nding male and female-specic gene sets by comparing septic versus healthy
individuals of male and female patients separately may be sensitive to signicance
cutos and low expressed genes in healthy individuals. Another transcriptomic
study by comparing transcription proles of patients from 12 hours to 28 days after
trauma, identied sex-specic dierences being related to lymphocyte regulation,
response to TGF- stimulus, ubiquitin-dependent protein catabolic processes, and
protein/macromolecule catabolic processing [Lopez et al., 2016]. Notably, the
authors compared the data from all time points together to identify dierentially
expressed genes between male and female patients. The temporal progression of the
disease was not accounted while identifying these dierences. These two studies
reported gender-dimorphism on the transcriptional level. However, they showed
very dierent results which may be due to neglecting the individual temporal
progression of the disease. This implies that transcriptomic investigations without
profound stratication can lead to non-reproducible observations.
The stratication can be achieved by implementing established scoring systems
such as Marshalls' Multiple Organ Dysfunction Score (MODS) and Sequential
Organ Failure Assessment (SOFA) score that are repetitive and designed for daily
bedside evaluation [Marshall et al., 1995, Vincent et al., 1996]. The scoring is based
on six dierent scores, one each for the respiratory, cardiovascular, renal, hepatic,
hematological and neurological systems. A high score correlates with increased
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hospital mortality [Marshall et al., 1995, Vincent et al., 1996]. The timely score also
reects the disease status of the patients such as pre-acute, acute and post-acute
phases of the disease. The patients can also be stratied based on their longitudinal
severity proles. Apart from organ dysfunction scores, variables of predisposition
(e.g. age), insult (e.g. blunt/penetrating trauma, infection) and response (e.g.
high/low biomarker levels, gene expression pattern, sepsis/septic shock) can be used
in the stratication model [Marshall, 2014]. The approach of stratication coupled
with transcriptomics is crucial in improving the reproducibility and interpretability
of the ndings.
An example of a clinico-transcriptomics approach was demonstrated by Rittirsch
et al. [Rittirsch et al., 2016]. They aimed at investigating mechanisms linked to
infection-related complications and sepsis-associated pathways after trauma.
Infection-related complications were clinically dened by the presence or the
absence of nosocomial infections. Using transcriptome analysis, the authors showed
that the genes of the heme-degradation pathway such as HP (Haptoglobin) and
HMOX1 (heme oxygenase-1) were signicantly upregulated in patients with sepsis
as compared to patients with systemic inammation without infection. Further, the
correlation with the clinical data revealed that patients who received allogeneic
blood transfusions had a higher incidence of nosocomial infections and sepsis. The
higher blood transfusion contributed to free heme which triggered higher expression
levels of genes from the heme-degradation pathway.
With the focus on identifying molecular responses associated with longer-term
post-injury complications in trauma patients, Desai et al. [Desai et al., 2011] also
implemented a clinico-transcriptomics approach in their study. They utilized the
MOF clinical score trajectories to cluster the patients into ve clinical categories of
increasingly poor outcome. Later, for each gene, fold change in the gene expression
was calculated per hour, per patient. Fold changes for each gene were then correlated
with the ve clinical categories to identify signicantly associated genes. In particular,
early downregulation of MHC-class II genes and upregulation of the p38 MAPK
signaling pathway were found to be strongly associated with longer-term post-injury
complications.
In summary, the combination of clinical and transcriptomic markers improves the
translational impact of molecular data and it represents a useful means for individual
risk stratication in trauma and sepsis patients.
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Objectives
Sepsis is dened as life-threatening organ dysfunction caused by a
dysregulated host response to infection. It manifests in complex forms, and the lack
of proper understanding further adds to a larger-scale failure in maximizing benets
from existing therapies and the discovery of novel eective treatments.
This thesis deals with sepsis and its sequelae to address three objectives: one
associated with the use of corticosteroids and the other two related to the sex-steroids.
The application of corticosteroids particularly hydrocortisone in septic shock
patients is controversial. A subset of patients is reported to benet in terms of shock
resolution and increased survival from the treatment while another is reported to
develop adverse eects including superinfections. The objective of this section was
to identify a theranostic marker that can guide the application of hydrocortisone in
septic shock patients in such a way that the benets will signicantly outweigh the
risks. If such a marker exists, then investigate the associated molecular mechanisms
to improve the understanding of the marker further.
The biological sex and sex-steroids in patients shape the basis for the underlying
immune and metabolic responses. However, previous studies exploring transcriptomic
sex dierences show only a minimal agreement among each other, possibly due to
neglecting the temporal progression and the synchronization of organ dysfunction
severities over time. To address this issue, the objective was to investigate a time
series of transcription proles of critically ill patients after trauma and develop a
statistical framework to synchronize these time series by considering the severity of
each patient. The goal was also to describe the evolving temporal transcriptional
regulation in peripheral immune cells of critically ill patients after trauma to explain
the better physiological response in premenopausal female patients.
The third objective of the thesis was concerning the modulation of sex-hormones
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during sepsis. The concomitant anti-androgenic and pro-estrogenic eects induced by
Flutamide (Flu) and Atraric acid (AA) independently are shown to improve survival
in male mice after polymicrobial sepsis. The goal of this study was to elucidate the
extent of femalization introduced by the treatment at the transcriptomic level and
identify the benecial alterations explaining the survival advantages observed in male
mice after polymicrobial sepsis.
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Materials and methods
3.1 The corticosteroids study
3.1.1 The CORTICUS cohort
The data for this study was collected by the CORTICUS Berlin study group
who, in addition to the standard CORTICUS protocol, sampled blood for
subsequent measurement of cytokines and other inammatory mediators from 84
patients in 13 participating sites. The study was approved by the local ethics
committee (ethics number 153/2001). Written informed consent was obtained from
patients, proxies or their legal representatives. Eligible patients were enrolled if they
met the following inclusion criteria: evidence of a systemic response to infection,
clinical evidence of infection, and the onset of shock within the previous 72 hours
and hypoperfusion or organ dysfunction attributable to sepsis. Major exclusion
criteria included an underlying disease with a poor prognosis, life expectancy less
than 24 hours, immunosuppression, and treatment with long-term corticosteroids
within the past 6 months or short-term corticosteroids within the past 4 weeks.
Detailed eligibility criteria is given in Appendix Tables A.1, A.2 and the original
study [Sprung et al., 2008]. Patients were randomized (in a 1:1 ratio) to receive
either a 50 mg intravenous bolus of hydrocortisone (HC) every 6 hours for 5 days,
followed by a tapered dose of 50 mg HC every 12 hours until day 8, and then 50 mg
HC once daily until day 11, or placebo. Data for baseline characteristics (before
onset of the study) were extracted from the CORTICUS database. 79 out of 83
(95%) patients received norepinephrine at baseline.
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Blood samples and serum assays of the CORTICUS Berlin sub-cohort
Blood samples were collected on day 0 (before the ACTH test and
HC/placebo treatment), on day 2, on the morning of day 5 (end of full dose HC
application), on day 12 (day after HC cessation), and on days 17 and 27. The short
corticotropin test was performed immediately before HC/placebo application using
blood samples taken before and 60 minutes after an intravenous bolus of 0.25 mg
cosyntropin (Novartis). Blood samples were stored at 4C for three hours to avoid
time imbalances between blood collection at dierent sites and further processing.
Serum and plasma were stored at -80C until further analysis. Heparinized and
EDTA whole blood samples were used for functional assays. At the time of the
CORTICUS study, soluble mediators, interleukin-(IL)-6, 8, 10, 12 p70, interferon-
(IFN), tumor necrosis factor alpha (TNF-), soluble FAS, soluble TNF-receptor I
(sTNF-RI) (all BD Biosciences OptEIATM Set Human), and E-selectin (R&D
systems) were measured in serum, plasma, or culture supernatant with
enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's
instructions. All measurements were done in duplicate. For the cytokines, EDTA
plasma was used. Hydrocortisol was measured from plasma. Surface antigens of
leukocytes were measured using ow cytometry, leukocytes in EDTA, thrombocytes
in citrate plasma (platelet enriched), caspase/BCL2 leukocytes with heparin. Serum
lactate was measured by routine blood gas analytics. Serum lactate was measured
for 51 patients at day 0. Among these, 41 patients were further observed daily for 3
days. All the blood and serum assays described above are performed by the
CORTICUS Berlin study group.
Calibration of the IFN/IL-10 threshold
The validation cohorts used in this analysis had dierent death rates. The HSSG
cohort had a much higher death rate compared to the discovery cohort (CORTICUS).
In order to address this discrepancy, the optimal IFN/IL-10 threshold for deciding
if the ratio is high or low was calibrated with the death rates. The CORTICUS data
was used to establish the calibration curve. In CORTICUS, the optimal threshold
was the 39.8 percentile of all 83 patients corresponding to the optimal ratio of 0.95
of IFN and IL-10 serum levels. This corresponds to the CORTICUS death rate of
27.7%. Several new datasets weighting the non-survived patients higher (or lower)
mimicking a higher (or lower) overall death rate were generated. For every newly
generated dataset, an optimal threshold is recalculated. A linear dependency of the
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threshold according to the death rate was observed, leading to the following linear
model,
thresholddeath rate = 35% + 0:215 death rate (in%)
Using this model, an optimal threshold was selected for each validation set
according to their death rates. The calibration curve applied to the validation
datasets is depicted in the Figure 4.2.
Regression analysis for lactate and norepinephrine consumption
A regression analysis was performed to study the time course of lactate. To
obtain the regression functions, patient-matched changes in lactate levels were
calculated for day 1, 2 and 3, relative to the baseline (day 0) for the available 41
patients. These patients were grouped into four sets: High IFN/IL-10 with
non-HC, high IFN/IL-10 with HC, low IFN/IL-10 with non-HC, and low
IFN/IL-10 with HC. To assess if there is the rate of change is signicant, a linear
regression t-test was performed on the time series of each patient for each panel a)
to d). In a linear regression t-test : A linear model,
y = b0 + b1x (3.1)
was set up for all 41 available patients in each group, in which y was the lactate level
and x was the time point (day). The test tests if b1 is not equal to zero, following a
t-statistics.
A similar regression analysis was performed for norepinephrine consumption rates.
The norepinephrine consumption at day 0, 1, 2 and 3 was investigated. These patients
were grouped into four groups as described above. To nd out if there is a signicant
rate of change, a linear regression t-test (as described above) was performed on the
time series of each group.
Interaction analysis of treatment and IFN/IL-10 levels
Using CORTICUS data, a two-way ANOVA was carried out in R. A linear
model for ANOVA was calculated using the `lm' function. 28-day survival was the
independent variable. Treatment and the IFN/IL-10 ratio were the dependent
variables. An F-test was applied to assess the signicance of the interaction
coecient (i.e. the coecient for the product of the treatment variable and the
IFN/IL-10 ratio variable).
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Adrenocorticotropic hormone (ACTH) test analysis
Machine learning on ACTH test data was performed using a similar cross
validation scheme as described in section 3.1.5. Two methods were applied, (1)
using the same decision tree implementation as used for the discovery set, and (2) a
linear discriminant analysis (LDA) employing the implementation from the `caret'
package of R [Kuhn, 2008]. The baseline cortisol level and the change in cortisol
upon stimulation were the two features in these models.
Transcriptional proling
Out of the 84 patients described above, 47 were randomly selected for
transcription proling with microarrays. Total RNA was isolated from whole blood
using the PAXgene Blood RNA Isolation kit (QIAGEN, Valencia, CA) according to
the manufacturer's instruction. Alpha and beta globin mRNAs were depleted using
the GLOBINclearkit (Ambion, Austin, TX). Transcriptomic proling was conducted
using Illumina Sentrix HumanWG-6 V2 BeadChip arrays containing  47,000 bead
types (Illumina, Inc., San Diego). The platform, its reproducibility and sensitivity
have been described in the FDA-guided Microarray Quality Control study (MAQC)
[MAQC Consortium, 2006]. Hybridization was performed according to the \Gene
Expression on Sentrix Arrays Direct Hybridization System Manual" (Illumina Inc.).
For each sample, total RNA was converted to double-stranded cDNA, followed by
amplication (in vitro transcription) to generate labeled cRNA. 1.5 g cRNA of
each sample was hybridized on a Sentrix BeadChip Array. After 16 h hybridization
time at a temperature of 58C for a volume of 30 l label incorporation was
performed by staining of hybridized arrays with 1g/l Streptavidin-Cy3
(FluoroLink Cy3, GE Biosciences, Pittsburgh, PA). Arrays were washed dried and
scanned immediately on an Illumina BeadArray Reader. BeadChips were scanned
by Gene Expression Module v3.2 according to the protocol of the manufacturer.
Transcriptional proling was performed by SIRS-Lab, Jena. The data was uploaded
to Gene Expression Omnibus (GSE106878).
Data analysis of the transcription proles
Normalization of gene expression proles and statistical analysis were performed
using R/Bioconductor (www.r-project.org). The data was log2 transformed followed
by quantile normalization using the `lumi' package [Du et al., 2008]. Probes with a
detection signicance P  0.05 were selected for further analysis. Probe annotations
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were processed using lumiHumanIDMapping and lumiHumanAll.db to get HGNC
symbols via Illumina nuIDs. Probes with the same gene annotation were merged by
averaging expression values using the function avereps of the `limma' package [Ritchie
et al., 2015]. The rst analysis compared the samples of patients before placebo/HC
treatment (0 hours) of 28 patients with IFN/IL-10 high versus 19 patients with
IFN/IL-10 low values. Genes with standard deviation or average expression above
the 25% percentile were selected and tested for signicant up- or down-regulation
using two-sided t-tests. Multiple testing correction was performed using the method
by Benjamini-Hochberg [Benjamini and Hochberg, 1995]. For better resolution of
functional gene sets, a lenient adjusted p-value cut-o of 0.2 was used for gene set
enrichment analysis. In the second analysis, the eect of HC on 7 IFN/IL-10 low-
ratio patients (benetting from HC therapy, responders) was observed by comparing
gene expression 48 h post start of the treatment versus pre-treatment (0 h). Genes
with standard deviation or average expression above the 25% percentile were selected.
Dierentially expressed genes were obtained using two-sided paired t-tests followed
by multiple testing correction (Benjamini-Hochberg [Benjamini and Hochberg, 1995],
FDR 0.1). A similar comparison was made with 12 low-ratio patients treated with
placebo. Genes distinctly up- or down-regulated in patients of the HC arm but not
in the placebo arm were selected for gene set enrichment analysis.
Gene set enrichment analysis was carried out using the R-package `gProleR'
with default parameters [Reimand et al., 2016]. A new method was developed to
reduce the redundancy among the signicant gene sets. Redundancy between two
gene sets was quantied using Jaccard similarity coecients, as dened below,
J(A;B) =
A \ B
A [ B (3.2)
where, A andB are gene sets containing signicantly dierentially expressed genes.
Gene set pairs with J(A;B) above a desired threshold were included in the model
and represented as an undirected graph, G = (X;E), with X as vertices and E as
edges of the graph. A linear model was set up with a constraint to select at most one
of the vertices of an edge:
Xi +Xj  1; for every fi; jg 2 E (3.3)
Xi = 0; or 1; for 1 i  n (3.4)
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With an objective function to:
maximize
X
wiXi (3.5)
where, wi is the weight of a gene set. The weight is derived from its signicance
(p-value) and calculated as 1   log10(p-value)=100. This maximization was done
employing linear integer programming solved by the software Gurobi [Gurobi
Optimization, 2016]. This lead to an optimal selection of at most one gene set from
a pair in such a way that the overall number of non-redundant gene sets are
maximized.
Assembling gene signatures of activated macrophages and T-cells
To get a gene signature of activated T-cells, normalized gene expression data
from a study by Grigoryev et al. [Grigoryev et al., 2009, Grigoryev et al., 2011]
(GEO accession number: GSE14352) was used. In their study, CD2+
T-lymphocytes were puried from peripheral blood mononuclear cells (PBMCs) of
10 healthy human donors. Non-activated CD2+ T-cells were resuspended in
RPMI-1640 complete media and activated with CD3/CD28 Dynal beads. RNA was
extracted using the mirVana miRNA Isolation Kit. The RNA was converted into
labeled cDNA using the GeneChip WT Sense Target Labeling kit (Aymetrix) and
the labeled cDNA was hybridized to Aymetrix Human Exon 1.0 ST arrays. Log2
transformed and quantile normalized data was obtained from Gene Expression
Omnibus. A comparison of 48 h post-activation samples with donor matching
(non-activated) controls and tests was performed for dierential expression using
paired two-sided Wilcoxon tests. Multiple-correction was performed using the
method of Benjamini-Hochberg [Benjamini and Hochberg, 1995]. The signicant
(adjusted p0.05) genes were assembled into a T-cell activation signature. The
macrophage (M1) activation signature was obtained based on gene expression
proles published by Xue et al. (GEO accession number GSE46903) [Xue et al.,
2014]. The authors puried monocytes from peripheral blood mononuclear cells
(PBMCs) of 15 human donors. Resting monocytes were resuspended in RPMI-1640
complete media, activated with GM-CSF for 72 h and further activated with IFN.
RNA was extracted with Trizol reagent, followed by clean-up and DNase I
treatment with QIAGEN RNeasy mini kit in accordance with the prescribed
protocol. Biotinylated cRNA were prepared with the Ambion MessageAmp kit for
Illumina arrays and hybridized to Illumina HumanHT-12 V3.0 expression beadchip.
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The raw data was downloaded from Gene Expression Omnibus, log2 transformation
and quantile normalization was performed in R using the `lumi' package [Du et al.,
2008]. A comparison between the expression proles of 17 activated (24 h and 72 h
post activation) samples with 19 non-activated samples was performed for
dierential expression using two-sided Wilcoxon tests. Multiple-correction was
performed using the method of Benjamini-Hochberg [Benjamini and Hochberg,
1995]. The signicant (adjusted p0.05) genes were assembled into a macrophage
activation signature. Two-sided Fisher's exact tests were performed to test for
enrichment of genes of interest in the T-cell and macrophage signatures.
Age stratication
In our CORTICUS sub cohort, the average age of the placebo patients was
69.4 years while for the HC patients it was 59.4 years. Therefore, the inuence of age
dierence was tested on the overall results. The weighted stratication was performed
as follows, the age of the youngest patient of the placebo group was 43 years. This
patient was counted at 100%. For each year a placebo patient was older than 43 years
we decreased the percentage of counting this patient by P. In turn, the oldest HC
patient was 87 years old. This was fully counted in the HC arm and we decreased
the percentage of being counted for all HC patients by the same amount P for each
year they are younger than 87 years. The value P was computed in such a way that
the average age in both the HC and the placebo groups were equalled out.
3.1.2 The HSSG cohort
Validation was performed on data of septic shock patients from the Hellenic
Sepsis Study Group (HSSG). This study included a prospective collection of clinical
data and biomaterial since 2006 of patients admitted in 45 hospitals in Greece. The
study protocol was approved from the Ethics Committees of all participating
hospitals. Patients were enrolled after written informed consent provided either by
themselves or by their immediate kin. Detailed eligibility criteria is given in
Appendix Tables A.1 and A.2. All the enrolled patients were reclassied according
to the Sepsis-3 classication criteria [Singer et al., 2016, Giamarellos-Bourboulis
et al., 2017]. The HC treated patients were administered with 50mg hydrocortisone
intravenously four times daily for 7 days followed by gradual tapering of the dose.
From serum of 342 patients, secreted cytokines were measured using the
LEGENDplex Human Inammation Panel (13-plex) (Bio-Legend) according to
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manufacturer's protocol with half of the reagents volume and sample incubation
time at 4C overnight. After quality control (discarding data from patients for
which either (1) both IFN and IL-10 cytokine levels were below the detection limit,
(2) the patient died or was discharged at the day of admission, (3) the serum was in
an experimental batch with more than 40% of the serum samples with undetected
IFN levels, or (4) bad consistency of the serum), a total of 162 eligible shock
patients (HC: n=63, No HC: n=99) were selected. If only one of the cytokines
(IFN or IL-10) was below the detection limit, the value of the detection limit was
taken.
Propensity score matching of HSSG cohort
The propensity score matching is a statistical method that ensures that the
distribution of baseline features (also called as `covariates') will be similar between
treated and untreated subjects in non-randomized clinical trials. For propensity
score matching, rst all available HSSG baseline clinical features (3 continuous, 11
binary and 1 categorical feature) were assessed for treatment bias using Fisher's
exact tests. For this testing, the features were binarized as follows: For every
continuous feature, four binary features were calculated based on their 25
percentiles. For example, for a continuous feature such as `age', four bins were
created (i.e. 1-25, 26-50, 51-75, 76-100 percentile). If a given patient has an age in
the proposed percentile bin it is regarded as 1 or 0 otherwise. For categorical
features, entry specic binary features were calculated. In total, this led to 25
binary features. Multiple-testing correction was performed employing the method
by Benjamini Hochberg [Benjamini and Hochberg, 1995]. The multiple corrections
did not lead to any signicant (p<0.1) features associated with the treatment.
However, two features, `history of renal disease' and `history of chronic heart failure'
were the top contributors of bias before multiple corrections. An ad-hoc analysis
was performed in order to study if the odds ratio (OR) is aected after propensity
score matching based on these two features. The propensity score matching and
selection of patients was performed using the `matchIt' package in R [Ho et al.,
2011] (`genetic algorithms', n=50,000 bootstrapping iterations).
3.1.3 The SISPCT cohort
The placebo-controlled, double-blind, randomized trial of Sodium Selenite and
Procalcitonin-guided antimicrobial therapy in Severe Sepsis (SISPCT) was
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performed in 33 hospitals in Germany. The purpose of this study was to determine
whether the selenium (in the form of sodium-selenite) treatment can reduce
mortality in patients with severe sepsis or septic shock. Additionally, it was
investigated, whether the measurement of procalcitonin - a marker of infection - can
be used to guide antimicrobial therapy during the disease course. Between the year
2009 and 2013, a total of 8,174 patients with septic shock or severe sepsis were
screened and 1,089 eligible patients with informed consent were randomized. Among
these, 109 patients (n=59 selenium-treated and n=50 placebo) were included in the
Munich (Ludwig-Maximilians-University, LMU) sub-study for which the cytokine
measurements of the blood samples (ethics vote amendment EudraCT:
2007{004333-42) were carried out. For this study, the selenium-treated patients, and
one patient who died at the day of inclusion were excluded. Secreted cytokine levels
in blood serum samples were measured by using the LEGENDplex Human
Inammation Panel (13-plex) (BioLegend) according to manufacturer's protocol
with half of the reagents volume and sample incubation time at 4C overnight. The
cytokine measurements were carried out in collaboration with the University clinic
Jena by Dr. Daniela Roll in the laboratory of Prof. Ralf Claus.
Propensity score matching of SISPCT cohort
For propensity score matching, rst all available SISPCT baseline features (4
continuous, 18 binary and 1 categorical feature) were tested for treatment bias
performing Fisher's exact tests. For this testing, the features were binarized as
described in the section 3.1.2. The binarization led to 40 binary features. Multiple
testing correction was performed employing the method by Benjamini Hochberg
[Benjamini and Hochberg, 1995]. Signicant features (p<0.1) were used for
propensity score matching comprising age, serum lactate, application of
inotrope/pressor drug, norepinephrine dosage, presence of septic shock (according to
ACCP/SCCM criteria), presence of severe sepsis (according to ACCP/SCCM
criteria) and kidney dysfunction. Finally, for propensity score matching and
selection of patients, the `matchIt' package in R [Ho et al., 2011] (genetic
algorithms, n=50,000 bootstrapping iterations) was applied, leading to 24 patients
with matched propensities.
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3.1.4 The Crossover study
A second validation was performed applying data from a double-blinded,
randomized, placebo-controlled, crossover study with 40 patients diagnosed with
septic shock. The study protocol was approved by the institutional ethics committee
[Keh et al., 2003]. Detailed eligibility criteria is given in Appendix Tables A.1 and
A.2. Until day 3, one arm received rst 100 mg loading dose of hydrocortisone and
10 mg per hour until Day 3 (n=20), followed by 3 days placebo. The other arm
received the rst three days placebo (n=20), followed by HC until day 6. Blood
samples were collected on day 0 (before randomization), and every subsequent day
until day 6. Enzyme-linked immunosorbent assays (ELISA) were used for
measurement of interleukin 4, 8, 10, 12 p70, and IFN (BD PharMingen, Germany),
soluble E-selectin (BenderMed Alexis, Austria), IL6 (R&D, Wiesbaden, Germany),
and soluble tumor necrosis factor receptors I and II (Biosource, Germany). The
cytokine measurements were requested from the authors of the study.
3.1.5 The rationale of the data analysis
The subcohort of CORICUS consisted of 83 patients and 137 patient features
(potential predictors) that were used to perform an exploratory data analysis. The
patient features also included the ratios of all cytokine combinations. The aim was to
nd one predictor which suits as a theranostic marker distinguishing HC responders
from non-responders. Patients that can benet from the HC treatment are referred
to as `HC responders' and others as `non-responders'. The workow is depicted in
Figure 3.1. The analysis started with nding the best predictor of survival (28
days) for the placebo arm (n=41). For this, one-level decision trees (stumps) were
calculated in a leave-one-out cross-validation scheme. The best decision trees were
chosen by intelligent enumeration. Among these, the predictor and threshold that was
present in the most of the trees (i.e. the predictor IFN/IL-10) was applied on the HC
arm. The threshold value was represented in the percentile of IFN/IL-10. Patients
whose predictor value ranked below the identied percentile were denoted as \low-
ratio patients", the others as \high-ratio patients". When all non-surviving patients
were weighted higher or lower, a linear relation between the optimal percentile and
the corresponding death rates was established. Hence, these optimal cutos were
calculated to gain a calibration curve with which the cuto for the validation sets
could be determined (details, 3.1.1). All analyses were carried out in R (www.r-
project.org) using custom scripts. Odds ratio and statistical signicance calculations
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are described in the next section.
Figure 3.1: The workow of theragnostic marker discovery and validation,
(A) The algorithm for the discovery of the theranostic marker, to note the term
\validation set" is used here within the context of the cross validation scheme:
(a) From all investigated CORTICUS patients, the placebo treated patients
are selected
(b) The selected patients are split into a training set (n=40) and a validation
set (n=1)
(c) Machine learning: Selection of the best predictor out of 137 available
predictors to predict survival on the training set, using one-predictor based
decision trees
(d) Testing the performance of the selected predictor on the validation set
(e) Adding the result from d) to the confusion matrix, and storing the tree
(f) Going back to b). In b) the next patient is forming the validation set, and
the rest of placebo patients are the training set
(g) From all stored trees, a consensus tree is determined (the one which has
been used most often, i.e. high IFN/IL-10 predicts survival, low IFN/IL-
10 predicts non-survival)
(B) The converted consensus tree (low IFN/IL-10 predicts survival, high IFN/IL-
10 predicts non-survival) is applied to the HC treated patients of CORTICUS,
HSSG, SISPCT, and to the early arm of the Crossover study. The consensus
tree is applied to the non-HC treated patients of HSSG and SISPCT.
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Calculation of odds ratio
Odds ratios were calculated by the following method. The ratio of survivors
to non-survivors that are treated according to the decision rule was computed. The
analogous ratio was computed for the rest of the patients that were treated opposite
to the rule. Finally, the odds ratio was computed by dividing these two ratios.
Analogously to clinical studies that compare \treatment" with \no treatment", in
this case \treated in compliance with the rule" were compared with \treated not in
compliance with the rule". The signicance of the odds ratio was calculated using a
one-sided Fisher's exact test.
3.1.6 Ex vivo whole blood culture experiments
To assess the plausibility of the data-driven biomarker IFN/IL-10, ex vivo
whole blood culture experiments were performed in which blood of healthy donors
was spiked with a broad range of bacterial lysates to simulate distinct pathogen
loads. 200 L of diluted (HBSS (1:1, V/V) heparinized whole blood obtained from
healthy volunteers (n=5, male, 20-25 years) was stimulated with serial dilutions of
lysates from E. coli isolates obtained from septic patients upon ethics approval. E.coli
lysates were created by sonication, following heat inactivation, and a serial dilution
of the obtained fragments stock was performed. Following exposition (37C, 18hrs,
gently agitation 2rpm) plasma supernatant was prepared by centrifugation (2.500xg,
RT, 10 min), secreted cytokine levels were measured using the LEGENDplex Human
Inammation Panel (13-plex) (BioLegend) according to the manufacturer's protocol
with half of the reagents volume and sample incubation time at 4C overnight. HBSS
was used as vehicle control. The experiments were carried out in collaboration with
the University clinic Jena by Dr. Daniela Roll.
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3.2 The longitudinal sex-dependant transcriptome
modulation study
3.2.1 The trauma cohort
The investigated cohort is a part of the retrospective observational study
`Inammation and host response to injury' (IHRI) (ClinicalTrials.gov identier:
NCT00257231). The cohort data used in the thesis was obtained from the
supplementary material of the original publication [Desai et al., 2011]. The most
important inclusion criteria for the cohort were: blunt trauma without isolated head
injury, blood transfusion within 12 hours of injury, base decit 6 or systolic blood
pressure <90 mmHg within 60 minutes after arrival at the emergency department
and the emergency department arrival 6 hours from time of injury. The major
exclusion criteria were: traumatic brain injury (dened as Glasgow Coma Scale
(GCS) motor score <3 or Abbreviated Injury Scale (AIS) score for head >4 within
24 hours of injury), anticipated survival of <24 hours from injury, pre-existing
immunosuppression or signicant pre-existing organ dysfunction. All the patients
were admitted within 12 h after injury and monitored for up to 28 hospital days.
For each patient, the rst blood sample was taken within 12 h after injury and
approximately 1, 4, 7, 14, 21, and 28 days after the injury. Leukocytes from whole
blood were isolated from peripheral blood samples (more details in ref. [Desai et al.,
2011]). Total cellular RNA was extracted and hybridized onto an HU133 Plus 2.0
GeneChip (Aymetrix) according to the manufacturer's recommendations.
3.2.2 Patient selection
Among the available data of 168 patients, a subset of 132 (85 male; 47 female)
was selected based on their age (between 16 to 50 years) and their maximum
Multiple Organ Failure (MOF) score without neuronal component >1 during their
rst 28 days in the hospital. These 132 patients were included in the severity
synchronization analysis. The upper age limit of 50 years was set to study the
response of premenopausal female compared to male patients. Among these 132
patients, for 129 (83 male, 46 female) there was at least one transcriptomic prole
available which could be mapped to the investigated time window of the
synchronized prole. Hence, these patients were included in the transcriptomic
analysis. A detailed patient selection scheme is given in Figure 3.2 below.
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Figure 3.2: A subset of 132 (85 male; 47 female) out of 168 patients were included in
the severity synchronization analysis. The selection was made based on their age, non-
complicated recovery proles (details in Figure 3.3) and the maximum MOF scores during
28-days from the time of injury. Among these, for 129 patients (83 male, 46 female)
transcriptomic proles were available which were matching to the time window of interest,
i.e. from 3 days before the acute phase to 3 days after the acute phase.
Patients with complicated MOF proles were excluded. A MOF score prole was
dened to be a complicated one if it contained two or more days with the highest MOF
score. An example of a complicated prole is shown in Figure 3.3A with an unstable
phase of more than 3 days. An unstable phase was dened as the days between
the rst day of the highest MOF score and the last day of the highest MOF score.
Patients were excluded if this unstable phase was >3 days. (B) The distribution of
the lengths of unstable phases across all patients is shown in Figure 3.3B.
3.2.3 Data retrieval and pre-processing
Microarray normalization and statistical analysis were performed using
R/Bioconductor (www.r-project.org). The raw data was background corrected and
RMA normalized using the `ay' package [Gautier et al., 2004]. Probe sets with a
detection signicance P0.05 were selected for further analysis. Probes were
mapped to their corresponding gene names (HGNC symbols) via Illumina nuIDs
using lumiHumanIDMapping and lumiHumanAll.db [Du et al., 2008]. Probes with
the same annotated gene were merged by averaging expression values using the
function avereps of the `limma' package [Ritchie et al., 2015].
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Figure 3.3: (A) An example of a complicated MOF score prole is shown here. An unstable
phase was dened as the days between the rst day of the highest MOF score and the last
day of the highest MOF score. (B) The distribution of the duration of unstable phases in
all patients.
3.2.4 The workow
The workow is depicted in Figure 3.4 summarizing the following steps:
1. Synchronization by severity to dene the acute phase
To make the time series expression proles comparable between patients, their severity
proles were synchronized. First, for each patient, the time point of the patient's most
severe state of the disease was identied by selecting the maximal Marshall MOF score
(without the neurological component, also in the following) within day 0 to day 28.
This selected day, the day of the highest MOF score was set as the `acute phase' for
that patient. If a patient had multiple days with the highest MOF score, the time
period between the rst and the last day with the highest MOF score was dened
as the `unstable phase'. An example is given in Figure 3.3A. Only patients with an
unstable phase shorter or equal to 3 days were included in the analysis (n=132) and
the whole time from the rst to the last day with highest MOF score was regarded as
the acute phase. The acute phase was set as a reference for aligning the other days
as explained in the next step.
2. Setting up the other phases
When regarding the transcription proles according to this reference day, a strong
increase and decrease in severity was observed within seven days, i.e. between day
-3 to +3 according to the reference day. Hence, this time window was used for
the analysis, i.e. seven days, 3 days before the acute phase, the day of the acute
phase and 3 days after the acute day. For simplication and to get enough samples
per analyzed time point, the window of seven days was categorized into ve major
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Figure 3.4: (A) The time series expression proles of the patients were synchronized
according to the day of maximal MOF (multiple organ failure) of the patients (denoted
as acute phase). (B) The investigated days before, at and after the acute phase were
binned into major temporal phases. (C) Sex-bias in the gene expression was quantied for
each phase and tested for signicant association with gene sets (D) The identied gene sets
were grouped according to their temporal appearance and further into the similar cellular
processes they describe.
phases. These phases were dened as `early pre-acute' (2 to 3 days prior to the acute
phase), `pre-acute' (1 day prior to the acute phase), `acute phase' (the most severe
day), `post-acute' (1 day after the acute phase) and `late post-acute' (2 to 3 days
after the acute phase). The distribution of the samples in each time point is given in
Table 3.1, comprising data from altogether 330 samples of 129 patients.
3. Gene expression analysis
Each of the ve temporal phases was analysed individually. The sex-bias in the
expression of each gene summarized in t-values (i.e. t-statistics) by comparing
transcription proles of male and female patients. Only the genes from autosomal
chromosomes were regarded. The t-values were used for gene set enrichment
analysis to select Gene Ontology terms employing the `piano' package [Varemo
et al., 2013] (n=50,000 permutations, choosing `mean' as the gene set statistics,
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Table 3.1: The distribution of microarray samples across the phases.
#Samples
Early
pre-acute
Pre-acute Acute Post-acute
Late
post-acute
Male 63 29 52 21 46
Female 31 17 28 19 24
distinct directional, the t-statistic were used). Gene sets of `Biological processes'
were taken as dened by Gene Ontology [Ashburner et al., 2000]. Highly
non-specic (containing more than 150 genes) and very small (less than 16 genes)
Gene Ontology terms were omitted. P-values resulting from the gene set enrichment
tests were corrected for multiple testing using the method by `Benjamini-Hochberg'
[Benjamini and Hochberg, 1995].
4. Clustering temporal proles of enriched gene sets
Gene sets with similar proles as per their temporal progression were clustered. For
this only those gene sets were considered which had high signicance (p<0.025) in
at least one of the time phases. LOD scores for gene sets were calculated as LOD
= -log10(p), where p were the adjusted p-values. These values were made directional
by adding a minus sign for gene sets which were downregulated in female patients.
The gene sets were separated into gene sets which were signicantly enriched in only
one phase (single phase cluster), and gene sets which were enriched in more than one
phase (multiple phase cluster). From each of these groups of gene sets, clusters were
formed according to the phase of their high signicance. These phase-specic clusters
were then separated into male and female clusters based on the directional LOD
scores. The functional relevance of the clusters was derived based on the biological
interpretation of their consisting gene sets.
3.2.5 Validating results by regarding transcription proles
from critically ill patients after burn injury
Validation was performed with a second publically available dataset. In this
study, patients were recruited under the observational and prospective study
conducted from 2000 to 2009 in four centres for burn injuries in the U.S. [Seok
et al., 2013]. These patients had a burn injury of over 20% of the Total Body
Surface Area (TBSA) and were admitted within 96 hours after the injury. Blood
was drawn from the time of injury until one year. The patients underwent at least
one excision and grafting surgery. Major exclusion criteria were: associated multiple
injuries exclusive of burns (Injury Severity Score (ISS) 25) and several
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pre-morbidity conditions (more details in ref. [Seok et al., 2013]). For validation,
only those patients for which transcription proles were available within the rst
week from the time point of injury were included. A subset of 103 (n=79 male;
n=24 female) patients between the age of 16 to 50 years was used in the analysis.
The raw data (downloaded from the NCBI GEO, accession number GSE37069) was
pre-processed and normalized as described above.
3.2.6 Additional statistical analyses
Distributions were visualized using boxplots of z-transformed expression values
of the gene sets of interest. Two-sided t-tests were performed to compare these
distributions between male and female patients and between male and female
healthy controls. The trend of MOF scores over time was studied using a linear
regression t-test. Wilcoxon rank-sum test was used to compare injury severity
scores, MOF scores and the distribution of day of maximum MOF between sexes
after synchronization. As the transcriptomic proling was originally carried out in
four batches, the impact of batch eect was estimated by checking the distribution
of male and female samples across batches. A chi-squared test was performed on the
distribution of number of male and female samples across the batches. However,
batch was not found to be a signicant (p>0.1) confounder. For the analysis of
severity-matched patients, a subset of acute phase samples of male and female
patients with comparable MOF and AIS (at inclusion) scores was selected. The
matching was performed using the `MatchIt' package (algorithm: `genetic') [Ho
et al., 2011].
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3.3 The sex-hormone modulation study in mice
3.3.1 Hormones and chemicals
Flutamide (Flu) was obtained from Sigma-Aldrich (Taufkirchen, Germany).
Atraric acid (AA) was kindly provided by Dr. Thomas Rosler from the Institute for
Pharmaceutical Chemistry, Philipps-University Marburg, Germany. For in vivo
experiments compounds were injected as homogenous suspensions in 0.9% NaCl
(Fresenius Bad Homburg, Germany) supplemented with 0.5% polysorbate 80
(Tween 80) (Sigma-Aldrich Taufkirchen, Germany) in deionized sterile water.
Solvent 0.9% NaCl supplemented with 0.5% Tween 80 was applied as a control in
male and female mice.
3.3.2 Peritoneal contamination and infection (PCI) model of
sepsis and transcriptome proling
A severe form of PCI sepsis model as described by Gonnert et al. [Gonnert et al.,
2011] was induced in C57BL/6 male and female mice aged between 12 to 16 weeks.
For synchronization of the pre-estrus cycle, female mice were set on male mice dung
three days before sepsis induction. For induction of sepsis, a 100% lethal dose (2 l/g
body weight) of a pre-adjusted (referred to male mouse survival) and microbiologically
characterized human feces batch was injected intraperitoneally. Treatment with the
compounds AA, Flu or solvent (0.5% Tween 80 in 0.9% NaCl) to male mice and
only solvent to the female control group was given subcutaneously at the time points
of 0 h, 4 h and 8 h after PCI induction. The compound administration was given
coincidently to the volume-resuscitation.
The experiment was terminated 10 h post-septic insult to assure the collection of
suitable samples of all animals (n=4 for each group). Mice were deeply anesthetized
with isourane and sacriced by heart puncture. The liver was dissected and snap
frozen in liquid nitrogen for transcriptome proling. Necropsy experiments were
performed simultaneously for all group to assure comparability. The obtained liver
tissues were thawed on ice and sections (50 mg  100 mg) were taken and placed in
1 ml of peqGOLD TriFastTM (Peqlab, Erlangen, Germany). A stainless steel bead
of 5 mm width was added to each tube. The reaction tubes were placed in a Tissue
Lyser (Qiagen Hilden, Germany) which homogenized the tissue for 3 min at 30 Hz.
Samples were veried to ensure that there was no visible debris and the bead was
removed with sterile forceps. The total RNA was isolated from mashed liver using
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the peqGOLD TriFastTM (Peqlab, Erlangen, Germany) according to the
manufacturer's instructions.
The transcriptome proling was performed using (MouseRef-8 v2.0 Expression
BeadChip containing  47000 bead types (Illumina Munich Germany). The
integrity of the isolated RNA was assessed based on 28S:18S rRNA ratio using
capillary electrophoresis system QIAxcel RNA QC Kit v2.0 (QIAGEN, Valencia,
CA). A 200ng input RNA from each sample was prepared according to
manufacturers protocol to obtain cRNA for chip hybridization using the
TargetAmpTM -Nano Labeling Kit for Illumina Expression BeadChip (Biozym,
Hessisch Oldendorf, Germany). To remove disturbing enzymes and nucleotides, a
clean-up step was executed using silica-based spin columns (Nucleospin RNA
clean-up, Macherey-Nagel, Duren, Germany). A total sample volume of 15 l was
hybridized on the BeadChip array. The dry BeadChip was placed in an iScan reader
to determine the transcriptional intensity of the respective gene, measuring
uorescence intensity as a surrogate.
The in vivo mouse study and transcriptome proling experiments were performed
by Dr. Daniela Roll. In this thesis, the analysis of these transcriptomic proles was
performed as described in the following sections.
3.3.3 Data analyses of the transcription proles
Normalization of transcription proles and statistical analysis were performed
using R/Bioconductor (www.r-project.org). The data was log2 transformed followed
by quantile normalization using the `lumi' package [Du et al., 2008]. Probes with a
detection signicance P  0.05 were selected for further analysis. Probes with the
same gene annotation were merged by averaging expression values using the function
avereps of the `limma' package [Ritchie et al., 2015].
Principal component analysis
Principal component analysis (PCA) summarizes the complexity in
high-dimensional data, such as transcriptome proles, while retaining trends and
patterns. It does it by an orthogonal transformation of several (possibly) correlated
features into a (smaller) number of uncorrelated features called principal
components. The rst principal component summarizes for as much of the variance
in the data as possible, and each following component accounts for as much of the
remaining variance as possible. The PCA was performed to study the
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transcriptomic shifts in the male mice as a consequence of the treatment. 10% of
the genes with the lowest standard deviation were removed and the principal
components (PCs) were derived using the prcomp function in R. The PCs being
orthogonal to each other, their addition or subtraction produces a transformed
vector that summarizes the two PCs. These transformed PCs were used to visualize
the inherent sex-dierences and female-like treatment eects in male septic mice.
Dierential gene expression analysis and gene set enrichment analysis
Dierential gene expression (DGE) analysis was carried out in R using the
`limma' package [Ritchie et al., 2015] using default parameters. This analysis was
carried out for three comparisons: (i) septic female (n=4) versus septic male (n=3),
(ii) AA treated male (n=4) versus solvent treated septic male (n=3) and, (iii) Flu
treated septic male (n=4) versus solvent treated septic male (n=3). Genes with
standard deviation or average expression above 25% percentile were selected and
tested for signicant up- or down-regulation. Multiple testing correction was
performed using the method by Benjamini-Hochberg [Benjamini and Hochberg,
1995]. An adjusted p-value cut-o of 0.05 was used to obtain signicantly
dierentially expressed genes. Co-directional genes (i.e. common up- or
down-regulated genes) between the comparisons (i) and (ii), were extracted to
study female-like eects of AA treatment and, similarly between (i) and (iii) to
study female-like eects of Flu treatment. Gene set enrichment analysis was carried
out using the R-package `gProleR' with default parameters [Reimand et al., 2016].
The redundancy among the signicant gene sets was reduced (using the method
described in the section 3.1.1 on page 18). After removing the redundancy, the
gene sets were further categorized on the basis of cellular processes they describe,
such as `anabolic processes', `cell death', `catabolic processes', `energy metabolism',
`growth response', `hormonal response', `homeostasis', `immune response',
`metabolic processes', `oxidative stress', `response to stimuli', `signaling processes',
`stress response', `transport' and `transcription and translation'.
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Results
4.1 The corticosteroids study
4.1.1 Patient characteristics
Patient characteristics such as height, weight, gender distribution, severities in
terms of SOFA and SAPS II scores, duration of ICU- and hospital- stay were similar
between the HC and placebo group. Age was signicantly lower in the HC group
(Table 4.1), but this was not found to be a confounder as described in section 3.1.1.
Mean plasma concentrations of soluble mediators and leukocytes measured at the
baseline (i.e. before treatment) were also similar between the HC and placebo group
[Kolte et al., 2018].
Table 4.1: Patient characteristics of the studied CORTICUS sub-cohort
HC (n=42) Placebo (n=41)
Sex (male/ female, n) 29/ 13 30/ 11
Age [years] 59.4 (22-87)* 69.4 (43-88)
Height [cm] 171 (150-188) 172 (150-195)
Weight [kg] 79.5 (50-130) 77.1 (53-127)
Admission category (n)
- Medical 1 0
- Emergency surgery 39 37
- Elective surgery 2 4
SOFA score at inclusion 10.4 (4-18) 9.8 (5-17)
SAPS II score
- First 24 hours at ICU 47.9 (22-80) 48.0 (16-88)
- Last 24 hours before inclusion 43.7 (13-77) 47.2 (16-88)
Time: sepsis to inclusion [hours] 29 (3-71) 31 (1-67)
ACTH Responder/ Non-Responder (n) 26/ 16 29/ 12
Survival (n)
- Day 28 (survivors/ non-survivors) 31/ 11 29/ 12
Continued on next page
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Table 4.1 { Continued from previous page
HC (n=42) Placebo (n=41)
- ICU (survivors/ non-survivors) 27/ 15 28/ 13
- Hospital (survivors/ non-survivors) 23/ 17 26/ 15
ICU-stay [days] all patients 27.5 (3-160) 23.9 (3-89)
ICU-stay [days] survivors 23.3 (5-73) 26.3 (3-89)
Hospital stay [days] all patients 51.3 (11-207) 45.5 (3-135)
Hospital stay [days] survivors 50.5 (15-128) 53.9 (17-135)
* : p < 0.05 ; Range : minimum and maximum
4.1.2 IFN/IL-10 straties CORTICUS patients
To identify the best treatment marker, the analysis of the baseline (blood
samples were taken before treatment and pre-randomization) characteristics of the
patients were considered. Baseline characteristics included 137 variables collected
from 83 patients (60 survivors, 23 non-survivors) including basic patient
characteristics and clinical variables, Sepsis-related Organ Failure Assessment
(SOFA) scores, lymphocyte counts and plasma protein concentrations of cytokines.
A leave-one-out cross-validation was performed with one-level decision trees
(consisting of only one predictor at a time) on the placebo arm to discriminate
between 28-day-survivors and non-survivors. This led to a high true positive rate
(83%, Table 4.2a). In 95% of the cross-validation runs, the serum IFN/IL-10 ratio
(also termed IFN/IL-10 in the following) with the same threshold (39.8 percentile
of IFN/IL-10 ratio from all patients) was selected by the algorithm as the best
predictor. Patients which IFN/IL-10 ratio ranked among the rst 39.8% patients
were denoted \low ratio patients", the others \high ratio patients". Upon applying
the predictor to HC-treated patients, the reverse behaviour was observed with a
high true negative rate, i.e. low IFN/IL-10 indicated a high likelihood of survival
(85%) (Table 4.2b). A signicant interaction eect (p=0.0083) was observed
between the ratio and the treatment (Figure 4.1). These observations were then
compiled into a decision rule: no HC treatment if the ratio was high, and HC
treatment if low. Following the decision(/treatment) rule yielded the odds ratio
(OR) of survival of 3.03 [95% Cl: 1.05-8.75], P=0.031. To note, IFN or IL-10 alone
were not suitable for this prediction. The identied new treatment rule was applied
to further, unseen data from additional clinical trials of septic shock (one larger
validation set and two smaller datasets from two further clinical studies).
37
Chapter 4 { Results
Figure 4.1: Interaction plot of treatment and IFN/IL-10 showed a signicant interaction
(p=0.0083) between treatment and the IFN/IL-10 ratio. Statistical details are given in
the section 3.1.1 on page 17.
Table 4.2: Survival rates in CORTICUS according to high and low IFN/IL-10
a) CORTICUS patients treated with placebo
Non-survivors Survivors % Survivors*
IFN/IL-10 high 4 20 83%
IFN/IL-10 low 8 9 53%
b) CORTICUS patients treated with HC (hydrocortisone)
Non-survivors Survivors % Survivors
IFN/IL-10 high 9 20 69%
IFN/IL-10 low 2 11 85%
* bold: in compliance with the decision rule.
4.1.3 Validation based on patients from the Hellenic Sepsis
Study Group (HSSG) and two further datasets
Table 4.3 shows the demographics of the patients used for validating the results.
Table 4.3: Patient characteristics of the studied HSSG cohort
HC (n=63) No HC (n=99)
Gender (male/ female, n) 32/31 38/61
Age [years] 71.10 (24.0-93.0) 73.10 (27.0-96.0)
SOFA 8.83 (2.0-20.0) 9.03 (2.0-21.0)
APACHE II 22.67 (7.0-41.0) 24.46 (3.0-52.0)
28 days survival (n, %) 20 (32%) 40 (40%)
Site of infection (n, %)
- Community-acquired pneumonia 33 (52%) 62 (63%)
- Intrabdominal infection 30 (48%) 37 (37%)
Continued on next page
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Table 4.3 { Continued from previous page
HC (n=63) No HC (n=99)
Co-morbidities (n, %)
- Presence of acute kidney injury 22 (35%) 25 (25%)
- History of diabetes mellitus type 2 21 (33%) 26 (26%)
- History of renal disease 3 (5%)* 16 (16%)
- History of chronic heart failure 11 (17%)* 34 (34%)
- History of chronic obstructive
pulmonary disease
11 (17%) 19 (19%)
* : p < 0.05 ; Range : minimum and maximum
Applying IFN/IL-10 ratio to the group of HSSG patients, a similar stratication
as for the CORTICUS patients was observed. High IFN/IL-10 indicated distinct
higher survival of the HC untreated patients (50% versus 19%), as shown in Table
4.4a. While, in the HC treated group an opposite behaviour (28% versus 35%) was
observed as shown in 4.4b, yielding an odds ratio of OR=2.01 [95% CI:1.04-3.88],
P=0.026. As the death rate of the HSSG patients was much higher compared to
CORTICUS, the threshold had to be adjusted according to a calibration scheme
based on the CORTICUS data as explained in the methods section 3.1.1 (on page
16). The calibration curve is depicted in Figure 4.2.
Figure 4.2: The calibration curve is depicted to set the percentile threshold of the predictor,
depending on the death rate of the study. The positive slope hints that as the death rate
increases more patients are needed to be treated with HC in order to obtain better survival.
HSSG had a death rate of 62.96%, hence the corresponding optimal threshold of 48.55
percentile was set. For SISPCT and the crossover study, the death rates were 16.33% and
30.00% corresponding to the 38.51 and 41.50 percentile, respectively
Figure 4.3a illustrates the enhanced survival of both studies and Figure 4.3b shows
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the forest plot. The HSSG cohort had an imbalance of two co-morbidities in the
HC treated and non-treated group. These co-morbidities were `history of chronic
heart failure' and the `history of renal disease'. To account for this imbalance in co-
morbidities, propensity score matching was performed (as described in section 3.1.2
on page 22) leading to the selection of 126 patients with survival OR=2.17 (95% CI:
1.02-4.63), p=0.032 in the patients following the rule. This conrmed that the existing
bias bias in the co-morbidities were not the contributing factors in the performance
of the predictor, IFN/IL-10.
(a)
(b)
Figure 4.3: Pie chart and Forest plot of CORTICUS and HSSG a) Survivors (red to
light red) and non-survivors (black to grey) of all patients (left) and of patients complying
with the proposed decision rule (right), patient numbers are given in the pies. Treatment
according to the rule led to an absolute risk reduction (ARR) of 0.14 [95% CI: 0.03-0.26].
b) Forest plot for the sub-cohorts of CORTICUS (discovery set), HSSG (validation set).
Below, the performance of the ACTH test is shown (details are given in section 4.1.9).
Furthermore, the performance of the marker was tested on two unseen
smaller datasets. The rst dataset included the patients from the placebo arm of
the randomized multi-center, placebo-controlled, trial of Sodium Selenite and
ProCalciTonin-guided antimicrobial therapy in Severe Sepsis (SISPCT)[Bloos et al.,
2016]. For this dataset, selenium-treated patients, and one patient who died at the
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Table 4.4: Survival rates in HSSG according to high and low IFN/IL-10
a) HSSG patients, untreated with HC
Non-survivors Survivors % Survivors*
IFN/IL-10 high 27 27 50%
IFN/IL-10 low 32 13 29%
b) HSSG patients treated with HC
Non-survivors Survivors % Survivors
IFN/IL-10 high 21 8 28%
IFN/IL-10 low 22 12 35%
* bold: in compliance with the decision rule.
day of inclusion were excluded. After propensity score matching, n=24 patients
were included in the analysis (details about the study and statistics, see section
3.1.3 on page 22). The treatment rule was found to be valid: 100% of the patients
survived (n=3) if treated according to the rule, compared to 77% if not treated
according to the rule, as shown in Table 4.5. In the second dataset the patients of
the early arm of the Crossover study [Keh et al., 2003] were included (for details
about this study and the crossover scheme, see section 3.1.4 on page 24). In this
study, the early arm got a comparable HC application as the HC arm of
CORTICUS, and hence was used for validating the marker. In line with the results
from CORTICUS, HSSG and SISPCT, low IFN/IL-10 showed better survival (88%
survivors), whereas high IFN/IL-10 was an indicator for considerably worse
outcome (57% survivors). The result is shown in Table 4.6. Due to the small sample
numbers, the odds ratio of survival from SISPCT and the crossover study were not
signicant. In summary, the investigated patients from all studies evidenced
IFN/IL-10 as a theranostic marker for HC application in septic shock.
4.1.4 Time courses of serum lactate and norepinephrine
requirement reect better recovery in patients treated
in compliance with the treatment rule
High serum lactate levels have been demonstrated to reect the degree of
metabolic derangements and increased mortality in sepsis patients [Singer et al.,
2016], hence lactate levels were included as an additional criteria in the new
denition of septic shock [Singer et al., 2016]. As measured in the CORTICUS
study, the median initial lactate in serum was 1.89 mmol/L in patients with high
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Table 4.5: Survival rates in SISPCT according to high and low IFN/IL-10
a) SISPCT patients, untreated with HC
Non-survivors Survivors % Survivors*
IFN/IL-10 high 0 8 100%
IFN/IL-10 low 0 6 100%
b) SISPCT patients treated with HC
Non-survivors Survivors % Survivors
IFN/IL-10 high 3 4 57%
IFN/IL-10 low 0 3 100%
* bold: in compliance with the decision rule.
Table 4.6: Patients from the early arm of the Crossover study (treated with HC,
similar to the CORTICUS HC arm)
Non-survivors Survivors % Survivors
IFN/IL-10 high 5 7 54%
IFN/IL-10 low 1 7 88%
* bold: in compliance with the decision rule.
IFN/IL-10, compared to 2.89 mmol/L in patients with low IFN/IL-10 suggesting
IFN/IL-10 to indicate the severity of cellular derangement in sepsis, analogous to
the lactate levels. To note, although lactate levels correlated inversely to the
IFN/IL-10, serum lactate itself performed worse as a theranostic marker, compared
to IFN/IL-10. Studying the time course of the rst 3 days after inclusion, lactate
levels overall decreased in all patient groups reecting their recovery. Notably, a
signicant rate of lactate decrease was explicitly identied in the group of patients
which were treated in compliance with the rule (Figure 4.4). Shock recovery reduces
the need for norepinephrine (NE) requirement. In line, the rate of norepinephrine
requirement decreased signicantly (P=2.0e-05) specically in the group of patients
in compliance with the rule (Figure 4.5). In summary, time series of serum lactate
and NE requirement reected better recovery of septic shock in patients treated in
compliance with the treatment rule.
4.1.5 IFN/IL-10 reects the pathogen load
In light of the observations described in the literature associating IFN and
IL-10 with the severity of parasitic and tuberculosis infection [Jamil et al., 2007],
it was hypothesized if IFN/IL-10 reects the immunological load of immune cells
when challenged with typical pathogens found in sepsis. The blood from healthy
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Figure 4.4: Baseline adjusted lactate levels, i.e. values for days 1-3 relative to day 0 for
each patient are presented. Absolute serum lactate levels and p-values for the change over
time in all available patients of the corresponding sub-group are reported in each panel.
Patients in panels (a) and (d) reect those in compliance with the treatment rule. For
patients with high IFN/IL-10, serum lactate decreased signicantly in the placebo arm
(P<0.01 n=11) (a), while its time course was rather heterogenous in the HC arm (n=13)
(b). Among the low-ratio patients, there was a tendency of decrease in the placebo arm,
however, not signicant (n=12) (c), in contrast to a signicant decrease in the HC arm
(P<0.01, n=5) (d).
donors was spiked with E. coli fragments from clinical isolates across a broad range
of concentrations, mimicking the immunological load. As expected, with increasing
load, IFN and IL-10 levels increased, but at varying degree. In terms of the ratio
kinetics, the inverse behaviour was observed, i.e. a high IFN/IL-10 was observed for
low pathogen concentrations and vice versa with an \on-o" kinetics (Figure 4.6).
This ratio kinetics conrms the hypothesis that a higher ratio associates with a lower
immunological load.
4.1.6 Genes for immune response and proliferation are
upregulated in patients with initial high IFN/IL-10
In the following, patients with an initial high ratio of IFN/IL-10 will be
denoted as \high ratio" patients. Using microarrays, the dierential gene expression
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Figure 4.5: Norepinephrine requirement for upto 3 days from enrollment is presented.
Patients in panels (a) and (d) reect those in compliance with the treatment rule. For
patients with high IFN/IL-10, NE requirement decreased signicantly in the placebo arm
(P<0.01 n=21) (a), while its time course was rather heterogenous in the HC arm (n=29) (b).
Among the low-ratio patients, there was a heterogeneous trend in the placebo arm (n=20)
(c), in contrast to a signicant decrease in the HC arm (P<0.01, n=21) (d). Putting the
compliant arms together (a and d), the rate of decrease over time was highly signicant
(p<2e-05), but not signicant in the non-complaint arm (panel b and c), p>0.5).
Figure 4.6: Whole blood from ve healthy donors was challenged with serial dilutions of
E. coli fragments mimicking the immunological load. (a) IFN and (b) IL-10 elevated with
increasing bacterial load while (c) their ratio showed the opposite behaviour, i.e. a high
load was associated with a lower ratio.
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of whole blood samples (drawn at baseline) was studied between high-ratio and
low-ratio patients. 689 genes were up- and 359 down-regulated in high-ratio
patients. Most prominently, upregulated genes in high-ratio patients were
signicantly enriched in immune response (14 gene sets, 151 genes), cell division (15
gene sets, 128 genes) and DNA repair (11 gene sets, 45 genes) categories. The ve
topmost signicant gene sets from each category are shown in Table 4.7.
Interestingly, about 20% of the upregulated genes were associated with proliferative
processes. There were not any gene sets being enriched with down regulated genes.
Table 4.7: Enriched sets of upregulated genes in initial high-ratio versus low-ratio
patients
* Gene set ID
Adjusted
p-value
Sig.
genes
IM viral transcription GO:0019083 6.80E-08 25
IM type I interferon signaling pathway GO:0060337 8.04E-05 13
IM defense response GO:0006952 8.65E-04 79
IM innate immune response GO:0045087 1.69E-03 49
IM immune response GO:0006955 3.25E-03 80
CD DNA replication GO:0006260 1.40E-09 36
CD telomere maintenance via recombination GO:0000722 2.43E-07 11
CD mitotic cell cycle GO:0000278 1.70E-06 67
CD G1/S transition of mitotic cell cycle GO:0000082 3.24E-06 26
CD cell cycle GO:0007049 5.52E-06 98
DR DNA repair GO:0006281 9.40E-07 44
DR DNA synthesis involved in DNA repair GO:0000731 6.48E-06 14
DR translesion synthesis GO:0019985 2.87E-04 9
DR mismatch repair GO:0006298 3.29E-04 8
DR nucleotide-excision repair, DNA gap lling GO:0006297 3.98E-04 7
DR error-prone translesion synthesis GO:0042276 1.04E-03 6
TR rRNA processing GO:0006364 1.19E-04 25
TR translational initiation GO:0006413 1.53E-04 21
TR ribonucleoprotein complex biogenesis GO:0022613 1.93E-04 36
TR translation GO:0006412 1.42E-03 42
TR translational termination GO:0006415 1.88E-02 11
SR cellular response to stress GO:0033554 2.28E-04 94
SR
endoplasmic reticulum unfolded protein
response
GO:0030968 1.50E-02 13
SR response to endoplasmic reticulum stress GO:0034976 2.50E-02 20
SR cellular response to stress GO:0033554 2.28E-04 94
SR
endoplasmic reticulum unfolded protein
response
GO:0030968 1.50E-02 13
SR response to endoplasmic reticulum stress GO:0034976 2.50E-02 20
MC DNA metabolic process GO:0006259 1.94E-08 72
MC protein targeting to membrane GO:0006612 8.60E-05 21
MC nuclear-transcribed mRNA catabolic process GO:0000956 2.66E-04 21
MC single-organism intracellular transport GO:1902582 6.83E-04 52
MC aromatic compound catabolic process GO:0019439 1.53E-03 32
Continued on next page
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Table 4.7 { Continued from previous page
* Gene set ID
Adjusted
p-value
Sig.
genes
* Categories: IM - Immune response, CD - Cell division, DR - DNA repair, TR -
Translation, SR - Stress response, MC - Miscellaneous
4.1.7 Upregulated genes in patients with high IFN/IL-10
overlap signicantly with gene signatures of activated
T-cells and macrophages
To elucidate if innate or adaptive immune cells express IFN and IL-10, their
expression in dierent immune cell types from healthy donors (data was taken from
[Petryszak et al., 2016]) was studied. IL-10 was found to be mainly expressed in
innate immune cells like macrophages and neutrophils, while, IFN was more
expressed in T-cells, together with natural killer and dendritic cells linking innate
and adaptive immunity (Figure 4.7), suggesting both immune systems to be
involved in the regulation of IFN/IL-10.
Figure 4.7: Data was taken from the Expression Atlas [Petryszak et al., 2016]. It was used
to compare gene expression in dierent immune cell types testing upregulation using one
sided t-tests. The intensity levels for the heatmap are represented as  log10(p  values).
Given these observations, it was hypothesized that the active state of these
major immune cell types might have contributed to the list of upregulated genes
in high-ratio patients. To test this hypothesis, the gene list was compared to gene
expression signatures of activated macrophages (representing innate immunity) and
activated T-cells (representing the adaptive immune system). Strikingly, genes of
interest were highly represented in the signatures of both cell types (T-cells: 301
genes, P<3e-22; M macrophages: 71 genes, P<2e-10, Table 4.8). The observed
overlap with activated T-cells was mainly due to cell division and DNA repair (The
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ve topmost signicant gene sets from each category are shown in Table 4.9). In
contrast, the gene overlap with activated macrophages showed gene sets of immune
response, such as interferon-gamma-mediated signalling, cytokine-mediated signalling
and antigen processing and presentation (The ten topmost signicant gene sets from
each category are shown in Table 4.10).
Table 4.8: Overlapping upregulated genes of initially IFN/IL-10 high patients with
T-cell and IFN-macrophage activation signatures
P < 3e-22
Upregulated genes in
IFN/IL-10 high
Not upregulated genes
in IFN/IL-10 high
Upregulated genes
in activated T-cells
301 409
Not upregulated
genes in activated
T-cells
312 9,573
P < 2e-10
Upregulated genes in
IFN/IL-10 high
Not upregulated genes
in IFN/IL-10 high
Upregulated genes
in activated IFN
macrophages
71 679
Not upregulated
genes in activated
IFN macrophages
48 11,593
Table 4.9: Enriched sets of upregulated genes in patients with high IFN/IL-10
overlapping with upregulated genes in activated T-cells
* Gene set ID
Adjusted
p-value
Sig.
genes
IM type I interferon signaling pathway GO:0060337 8.09E-04 8
IM
regulation by virus of viral protein levels in
host cell
GO:0046719 1.12E-03 4
IM
somatic hypermutation of immunoglobulin
genes
GO:0016446 1.73E-03 4
IM viral transcription GO:0019083 1.01E-02 10
CD DNA-dependent DNA replication GO:0006261 7.53E-11 20
CD cell cycle G1/S phase transition GO:0044843 7.06E-10 25
CD DNA strand elongation GO:0022616 1.51E-06 7
CD regulation of cell cycle GO:0051726 1.69E-05 42
CD DNA biosynthetic process GO:0071897 3.46E-05 16
DR interstrand cross-link repair GO:0036297 7.38E-03 6
DR error-prone translesion synthesis GO:0042276 1.12E-02 4
DR DNA ligation GO:0006266 1.77E-02 4
DR strand displacement GO:0000732 4.45E-02 4
Continued on next page
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Table 4.9 { Continued from previous page
* Gene set ID
Adjusted
p-value
Sig.
genes
SR cellular response to stress GO:0033554 1.70E-05 64
TR mitochondrial translation GO:0032543 2.53E-05 13
MC
protein modication by small protein
conjugation
GO:0032446 1.01E-03 35
MC
positive regulation of protein ubiquitination
involved in ubiquitin-dependent protein
catabolic process
GO:2000060 1.28E-03 9
MC
positive regulation of gene expression,
epigenetic
GO:0045815 9.26E-03 7
MC protein-DNA complex assembly GO:0065004 1.10E-02 12
MC
macromolecular complex subunit
organization
GO:0043933 1.15E-02 55
* Categories: IM - Immune response, CD - Cell division, DR - DNA repair, TR -
Translation, SR - Stress response, MC - Miscellaneous
Table 4.10: Enriched sets of upregulated genes in patients with high IFN/IL-10
overlapping with upregulated genes in activated macrophages
* Gene set ID
Adjusted
p-value
Sig.
genes
IM cytokine-mediated signaling pathway GO:0019221 3.02E-10 18
IM type I interferon signaling pathway GO:0060337 5.66E-10 9
IM immune system process GO:0002376 2.47E-08 34
IM regulation of innate immune response GO:0045088 3.57E-08 14
IM defense response to virus GO:0051607 3.43E-07 10
IM
antigen processing and presentation of
exogenous peptide antigen via MHC class I,
TAP-dependent
GO:0002479 1.20E-06 7
IM cytokine production GO:0001816 1.80E-05 14
IM
interferon-gamma-mediated signaling
pathway
GO:0060333 3.94E-05 6
IM
tumor necrosis factor-mediated signaling
pathway
GO:0033209 2.12E-04 7
IM activation of immune response GO:0002253 4.50E-04 11
MC protein deubiquitination GO:0016579 4.46E-04 8
MC
regulation of cellular ketone metabolic
process
GO:0010565 1.56E-03 6
MC protein polyubiquitination GO:0000209 9.50E-03 7
MC
negative regulation of protein modication
process
GO:0031400 2.46E-02 9
* Categories: IM - Immune response, MC - Miscellaneous
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4.1.8 HC upregulates immune response in patients with low
IFN/IL-10
According to the treatment rule, HC treatment improves survival in patients
with low IFN/IL-10 (\responders" in the following). To study the change in
regulation in this group upon HC treatment, gene expression at 24 h after the rst
HC treatment was compared to 0 h, specically in the responders (and not
dierentially expressed in the non-responders). The comparison identied 301 up-
and 210 genes being down-regulated. Gene set enrichment analysis revealed that
most of the upregulated genes belonged to the immune system. The up- and
down-regulated enriched gene sets are shown in Table 4.11 and Table 4.12,
respectively.
Table 4.11: Enriched sets of upregulated genes (24h versus 0h) of the responders
* Gene set ID
Adjusted
p-value
Sig.
genes
IM defense response GO:0006952 2.76E-03 44
IM regulation of defense response GO:0031347 3.21E-03 26
IM cytokine production GO:0001816 4.00E-03 25
IM immune response GO:0006955 1.06E-02 44
IM innate immune response GO:0045087 2.76E-02 27
IM cellular response to biotic stimulus GO:0071216 3.46E-02 11
IM immune system process GO:0002376 3.47E-02 59
IM response to molecule of bacterial origin GO:0002237 3.79E-02 15
IM
antigen processing and presentation of
exogenous peptide antigen via MHC class I,
TAP-independent
GO:0002480 3.95E-02 3
IM response to abiotic stimulus GO:0009628 2.27E-02 34
MC organic cyclic compound catabolic process GO:1901361 3.04E-02 19
MC regulation of multicellular organismal process GO:0051239 4.78E-02 63
* Categories: IM - Immune response, MC - Miscellaneous
Table 4.12: Enriched sets of downregulated genes (24h versus 0h) of the responders
* Gene set ID
Adjusted
p-value
Sig.
genes
MC
cellular modied amino acid biosynthetic
process
GO:0042398 4.86E-02 5
* Categories: MC - Miscellaneous
Strikingly, this was very similar to the list from the previous section when
comparing initial IFN/IL-10 high- versus low- patients. Indeed, a signicant
overlaps (Table 4.13) of the two gene lists for upregulation (n = 24, P<3e-03) and
downregulation (n = 23, P<1e-09) was observed. Again, mainly genes for the
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immune response were commonly upregulated. Notably, this included all three
members of the butyrophilin subfamily 3, named BTN3A1, BTN3A2 and BTN3A3.
Commonly downregulated genes did not show any signicantly enriched gene set. In
summary, gene expression of the responders suggests recovery of immune cell
function on the gene regulatory level, similar to the initial high-ratio patients for
which no HC treatment is recommended by the treatment rule.
Table 4.13: Overlapping upregulated genes of initially IFN/IL-10 high patients with
the upregulated genes of the responders after 24 hours
P < 3e-03
Upregulated genes in
patients with high
IFN/IL-10 before
treatment
Not upregulated
genes in patients
with high
IFN/IL-10 before
treatment
Upregulated genes in
the responders
24 277
Not upregulated
genes in the
responders
656 15072
P < 1e-09
Downregulated genes
in patients with high
IFN/IL-10 before
treatment
Not downregulated
genes in patients
with high
IFN/IL-10 before
treatment
Downregulated genes
in the responders
23 187
Not downregulated
genes in the
responders
336 15492
4.1.9 The corticotropin stimulation test
The corticotropin stimulation test (a.k.a ACTH test) has been used to assess
the adrenal functions and hence in the decision-making of hydrocortisone treatment.
However, poor response to corticotropin stimulation is no longer recommended for
hydrocortisone treatment in septic shock patients [Annane et al., 2002]. To improve
the performance of this test, additional machine learning concepts were
implemented to stratify for treatment using serum hydrocortisone at baseline and
after corticotropin stimulation. In line to the results of the original study [Sprung
et al., 2008], the corticotropin test failed to predict a better response to treatment.
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The best performance resulted in OR = 0.92 [95% CI: 0.35-2.40] as shown in Figure
4.3b.
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4.2 The longitudinal sex-dependent transcriptome
modulation study
4.2.1 Stratifying severity in patients followed by
transcriptomic analysis
For the studied 132 patients, the dierence in their Abbreviated Injury Scale
(AIS) score at admission was non-signicant between sexes (male patients:
AIS=3.99 (95% CI: 3.81-4.17); female patients: AIS=4.15 (95% CI: 3.91-4.39),
4.8A). Independent from gender, heterogeneous severity proles were observed when
comparing them in respect to the temporal progression. To address this,
synchronization was performed in such a way that the day of highest disease
severity (peak of the MOF scores, the most severe day) was matched for all proles.
After synchronization, the distribution of the day of highest severity was
comparable between male and female patients (Figure 4.9). Accordingly, also the
transcription proles were synchronized by the day with the maximal MOF score.
The synchronization provided a distinct phase of increasing severity (increasing
MOF), highest severity (MOF peak) and declining severity (declining MOF), as
shown in Figure 4.8B.
As the patients showed this strong increase and decrease of severity within a seven
days window, this window of 7-days, i.e. 3 days before the most severe day, the most
severe day and 3 days after the most severe day was the focus in the following analysis.
During this window, male patients showed a signicantly (p<0.01) higher degree of
organ dysfunction than female patients. For simplicity, the phases were binned into
ve sets comprising `early pre-acute' (2 to 3 days prior to the most severe day), `acute
phase' (the most severe day), `pre-acute' (1 day prior to the acute phase), `post-acute'
(1 day after the acute phase) and `late post-acute' (2 to 3 days after the acute phase).
For each phase dierential expression analysis was carried out to obtain
dierentially expressed gene sets between male and female patients. These gene sets
were grouped according to their signicance across the temporal phases. The
functional relevence of the clusters was derived based on the biological
interpretation of their consisting gene sets [Kolte and Konig, 2019].
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Figure 4.8: (A) At admission, the abbreviated injury scale (AIS) score was comparable
between the sexes (male patients: AIS=3.99 (95% CI: 3.81-4.17), female patients: AIS=4.15
(95% CI: 3.91-4.39; p > 0.3)). (B) The Marshall MOF score (without neurological
components) of the synchronized proles was higher in male patients at the later time
points.
Figure 4.9: Male and female patients showed a similar distribution of the highest MOF
score after baseline. To note there was no signicant (p>0.1, Wilcoxon rank-sum test)
dierence in the distributions.
4.2.2 The innate immune response is upregulated in the early
pre-acute phase of female patients
The early pre-acute phase was dened as the period of 2 to 3 days prior to the
acute phase. As expected from the synchronization, there was a signicant (p<0.0001)
rate of increase in the MOF score from this phase to the acute phase across male and
female patients. The transcriptomics comparison at this phase revealed a distinct
higher regulation of a broader set of genes associated with an acute-phase response in
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female patients compared to male patients. A total of seven gene sets related to the
innate immune response were identied in this cluster specic to females in the early
pre-acute phase. These included positive regulation of NF-B transcription activity,
myeloid dendritic cell dierentiation and chemotaxis, cytokine response, and, more
specically IL-7 mediated signaling. Figure 4.10A shows the temporal proles of all
identied gene sets corresponding to the innate immune response. Appendix Figure
A.2 shows all gene sets of this cluster which were upregulated in females during this
phase.
In line, another cluster was identied consisting of upregulated gene sets in
female patients. In this cluster, gene sets were upregulated in at least two of the
rst three temporal phases of the disease, i.e. in the early pre-acute, pre-acute and
acute phases. Also, this cluster contained innate immunity-related gene sets, such as
cellular response to tumour necrosis factor, positive regulation of ERK1-ERK2
cascade, and neutrophil chemotaxis. Appendix Figure A.1 shows the temporal
proles of all gene sets in this cluster. The expression of genes from these seven
gene sets of innate immunity from the rst cluster was compared to their expression
in healthy controls and observed that in both sexes these gene sets were
upregulated, and in the female patients, these sets were signicantly more
upregulated (Figure 4.10B). The other gene sets of both clusters contained sets for
further signaling processes like phosphatidylinositol mediated signaling,
transcriptional regulatory processes, protein modication and neural processes
(Appendix Figure A.2 and A.1).
4.2.3 Wound healing and recovery processes are upregulated
early in female patients
During the pre-acute and the acute phase, a distinct upregulation of recovery
processes was observed in female patients. The upregulated gene sets at the
pre-acute phase were predominantly associated with the stages of early wound
healing such as tissue restoration and blood coagulation. These included positive
regulation of vasoconstriction, platelet activation, blood coagulation, intrinsic
pathway and platelet degranulation. The process of brinolysis was also upregulated
in female patients. Simultaneously, an upregulation of cellular processes governing
leukocyte migration and positive regulation of phagocytosis, together with signaling
processes such as positive regulation of MAPK cascade in female patients was
observed. There were eleven gene sets identied in this cluster related to the early
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Figure 4.10: (A) The cluster of the early pre-acute phase consisted of 16 gene sets being
upregulated in female patients. They comprised seven gene sets of the innate immune
response. These gene sets are shown here. The complete list is given in Appendix Figure
A.2. (B) For the same phase, in comparison to healthy controls, leukocytes of both sexes
showed a higher expression of genes for the innate immune response. A distinctively higher
expression was observed in female patients. (C) Gene set clusters of the late post-acute
phase consisted of 17 gene sets being upregulated in female patients, nine were related
to the adaptive immune response. These gene sets are shown here. The complete list is
given in Appendix Figure A.3. (D) For the same phase, in comparison to healthy controls,
leukocytes of female patients showed upregulation of the adaptive immune response. These
gene sets were similarly expressed in male patients and healthy controls. The signicance of
dierence between male and female was tested using two-sided Student's t-tests (* P<0.05,
mean bar and Whiskers of the boxplots: meanse).
wound healing response. Figure 4.11A shows the temporal proles and lists of
representative gene sets. The complete cluster is given in Appendix Figure A.4.
During the acute phase, the most prominent upregulated gene sets in leukocytes of
female patients were growth and development related gene sets. These included
anterior/posterior pattern specication, artery morphogenesis, skeletal system
development and gene sets for several neural processes. Upstream to these, response
to IL-1 signaling and cytokine-mediated signaling were also upregulated. This
cluster consisted of eleven gene sets for growth and developmental processes. Figure
4.11C shows the temporal proles and lists of representative gene sets, while the
complete cluster is given in Appendix Figure A.5. To note, the eleven gene sets for
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early wound healing in the pre-acute phase and another eleven gene sets for growth
and developmental processes in the acute phase were upregulated in male and
female patients, when compared to healthy individuals. Still, these gene sets showed
signicantly higher expression in female compared to trauma male patients (Figure
4.11B, D).
Figure 4.11: (A) The cluster of the pre-acute phase contained 11 gene sets being
upregulated in leukocytes of female patients. These gene sets are all related to wound
healing processes. Eight representative gene sets are shown here. The complete set is given
in Appendix Figure A.4. (B) In comparison to healthy controls, the gene sets were higher
expressed in the leukocytes of both sexes. A distinctively higher expression was observed
in the leukocytes of female patients. (C) The cluster of the acute phase contained 19 gene
sets being upregulated in female patients. Eleven of these were associated with growth
and development. Four representative gene sets are listed here. The complete list is given
in Appendix Figure A.5. (D) In comparison to healthy controls, leukocytes of both sexes
showed a higher expression of these gene sets, distinctively higher expression was observed
in leukocytes of female patients. The signicance of dierence between male and female was
tested using two-sided Student's t-tests (* P<0.05, mean bar and whiskers of the boxplots:
meanse).
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4.2.4 During the pre-acute and acute phases, genes for
transcription and translation, cell cycle, DNA damage
and repair and oxidative phosphorylation are
downregulated in female patients
Two third of the identied sex-specic transcriptomic gene sets were
downregulated in female compared to male patients. Most of these gene sets were
observed within the rst three phases, i.e. during the early pre-acute, pre-acute and
acute phases. These gene sets were grouped into two larger clusters. One cluster
comprised gene sets that were downregulated in at least two of rst three phases i.e.
early pre-acute, pre-acute and acute phase, (Figure 4.13), and the other cluster
comprised gene sets which were downregulated only in the acute phase (Appendix
Figure A.6).
The rst cluster contained gene sets related to cell cycle, transcription and
translation, DNA damage and repair and energy metabolism including oxidative
phosphorylation (OxPhos). Compared to healthy individuals, the expression of
these gene sets was downregulated in both sexes of the patients. Figure 4.13 shows
the temporal proles and their representative gene sets. The complete cluster is
given in Appendix Figure A.6. Still, these gene sets were distinctively more
downregulated in female than in male patients.
Figure 4.12: In comparison
to healthy individuals, energy
metabolism gene sets were
downregulated in female
patients during the acute
phase. The expression of the
genes from these gene sets in
male patients was comparable
to healthy controls (* P<0.05,
two-sided Students' t-test ;
meanse).
ATP
producing processes such
as regulation of glycolytic
processes, TCA cycle,
fatty acid beta-oxidation and
electron transport chain were
signicantly down regulated
in female, compared to
male patients. In line, ATP
consuming processes were
also downregulated in female
patients, such as DNA repair by excision mechanisms, RNA processing, and
specically transcription via RNA polymerase I, II and III, RNA transport, RNA
splicing, tRNA processing, tRNA modication, RNA metabolism etc. and gene sets
for cell cycle comprising DNA replication to telomerase maintenance, transition of
mitotic cell cycle, mitotic spindle assembly checkpoint, chromosome segregation and
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anaphase promoting complex-dependent catabolic process.
Figure 4.13: (A) The cluster consisted of 85 gene sets being downregulated in female
patients. Most of these were associated to (B) energy metabolism and the mitochondrion
(11 gene sets), (C) cell cycle (21 gene sets), (D) transcription and translation (26 gene
sets), and (D) damage and repair (9 gene sets). For each category, three representative
gene sets are listed here. The complete list is given in A.7. In comparison to healthy
controls, for all categories, leukocytes of both sexes showed a lower expression of these gene
sets, but relatively lower expression was observed in female patients. The signicance of this
dierence between male and female was tested using two-sided Student's t-tests (* P<0.05,
mean bar and whiskers of the boxplots: meanse).
The second cluster comprised gene sets which were again related to transcription
and translation, DNA damage and repair, and energy-metabolism (Appendix Figure
A.6). In comparison to healthy individuals, these gene sets were downregulated in
male and female patients during the acute phase, except for energy metabolism
related gene sets. The gene expression of energy metabolism related gene sets in
male patients was comparable to the healthy individuals (Figure 4.12). In summary,
cell cycle, repair, and energy producing and ATP consuming processes were
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distinctively downregulated in female, compared to male patients in the pre-acute
and acute phases.
4.2.5 Genes coding for the adaptive immune response are
distinctively higher expressed in the late post-acute
phase of female patients
After the acute phase, as expected from the synchronization, the MOF scores
declined at a signicant rate (p<0.0001) reecting a phase of recovery in male and
female patients. In female patients, the recovery was observed also at the molecular
level. In the late post-acute phase i.e. 2 to 3 days after the acute phase, a distinct
upregulation of genes of the adaptive immune system was observed in female patients.
This comprised T cell activation, T cell co-stimulation, T cell dierentiation and
positive regulation of T cell proliferation. Additionally, in female patients, a distinct
upregulation of cytokine production, and particularly of IL-4 production was observed,
together with the upregulation of negative regulation of type I interferon production.
Also, gene sets related to B cell activation, B cell receptor signaling was upregulated
in female, compared to male patients. Figure 4.10C shows the temporal proles of
gene sets from the adaptive immunity cluster. This cluster consisted of nine gene sets
out of which ve representatives are listed. The complete cluster is given in Appendix
Figure A.3. Comparing the expression proles with the proles of healthy individuals,
showed that these nine gene sets for adaptive immunity were upregulated only in
female patients. Male patients expressed these comparable to the controls (Figure
4.10D). In summary, leukocytes of female patients showed a distinct higher expression
of genes being responsible for restoring the adaptive immune system during this late
post-acute phase.
4.2.6 The divergent regulation can be attributed to gender
dimorphism rather than to the dierent disease
severities
Male patients showed more MOF compared to female patients in the acute
phase. Thus, the identied transcriptomic dierences between male and female
patients could have been due to the dierences in the severity but not directly
associated with gender dimorphism. To justify if the identied transcriptomic
dierences can be attributed to the sexes but not to the severity alone, an analysis
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was performed in which a subset of transcription proles (n=28 female, n=23 male
patients) from the acute phase were selected in such a way that the MOF scores and
AIS scores of the corresponding male and female patients were comparable at the
acute phase. Comparing the transcriptional proles of male versus female samples
showed 123 gene sets to be signicantly dierentially expressed, out of which 114
(93%) were identical to the previously identied gene sets during the acute phase
(Figure 4.14). As expected, the downregulated gene sets in female patients were
associated with transcription and translation, cell cycle, DNA damage and repair,
and oxidative phosphorylation, while upregulated gene sets were related to innate
immune response, and growth and development. In summary, the identied gene
sets by comparing male versus female patients were not due to the dierences in the
severities but the gender dimorphism itself.
Figure 4.14: Comparison of dierentially expressed gene sets prior and after severity
matching in the acute phase.
4.2.7 Similar gender dimorphism of gene regulation in the
blood of trauma patients and patients with severe burn
injury
The transcription proles of patients with severe burn injuries were studied to
validate the main ndings from the trauma study. The patients were 16-50 years
old with injury severity scores above 25. As the longitudinal severity scores were not
available for synchronization, the transcriptomic response of the rst week after burn
injury was investigated. The transcriptomic gender dimorphism in these patients was
found comparable to the pre-acute and acute phase of trauma patients. This included
upregulation of the innate immune response, wound healing and growth processes,
and downregulation of transcription and translation, cell cycle, DNA damage and
repair and energy metabolism in female patients with burn injury (Figure 4.15).
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The adaptive immune response in these patients was overall suppressed and identical
between sexes during the rst week of burn injury. Notably, female patients showed
signicant upregulation of the adaptive immune response after the rst week. These
results support the main ndings observed for patients after blunt trauma.
Figure 4.15: The gure depicts the expression levels in patients with severe burn injury and
healthy individuals for the identied sex-specic gene sets in the early pre-acute, pre-acute,
acute and late post-acute phases of the trauma patients. A) and B) represent the immune
response related modules and their expression levels. C) and D) represent the healing
response and, growth and development modules. E) to H) represent the downregulated gene
sets related to the bioenergetics and housekeeping molecular processes. The signicance of
dierence between male and female was checked using two-sided Student's t-tests (* P<0.05,
mean bar and whiskers of the boxplots: meanse).
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4.3 The sex-hormone modulation study in mice
4.3.1 The treatments induce a transcriptomic shift in septic
male mice towards septic female mice
The gender dimorphic septic response and the eects of Atraric acid (AA) or
Flutamide (Flu) treatment on septic male mice was interrogated at the
transcriptomic level. The total variance in the entire dataset was summarized using
principal component analysis (PCA). The rst four principal components (PCs)
explained nearly 75% variance of the whole dataset. Both, the rst and second PCs
distinctly separated solvent treated septic male and septic female mice (Figure
4.16). The dierence between the treatments was captured in the third component.
Furthermore, the rst component marginally partitioned between female mice
against solvent or compound treated males. The second component, in addition to
the male-female separation, clustered the treated male mice to the female side;
thereby, indicating transcriptomic shift introduced by compounds in septic males
towards females. To further rene the transcriptomic shift caused by the treatments
and gender dierences, the combination of PCs were used as shown in Figure 4.16.
As PCs are linear orthogonal axes, diagonal axis to any two PCs can summarize the
information ascribed in them. The gender dierences were distinct along the
PC1   PC2 axis (Figure 4.16a), while female-like eects of the treatment were
apparent from the PC2 + PC4 axis (Figure 4.16b). It is important to note that the
`female-like' eects of the treatments are essentially the subset of the gender
dierences that are inuenced by the treatments.
4.3.2 Septic female mice downregulate immune response,
redox processes, energy processes and cell death
mechanisms in liver
Under septic conditions, the liver transcriptomic response of pre-estrus females
diered from males in immune, metabolic and cellular processes. The comparison
led to 467 up- and 367 down-regulated genes in females. The immune response was
predominately downregulated with distinct downregulation of gene sets such as
acute-phase response, response to lipopolysaccharides and interleukin response
particularly response to interleukin-1. This was accompanied by downregulation of
energy metabolism. Gene sets such as generation of precursor metabolites and
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(a)
(b)
Figure 4.16: a) PC1 (explaining 34.4% variance) - PC2 (explaining 23.1% variance)
highlights the presence of inherent gender dierences unaected by the treatments. b)
while, PC2 (explaining 23.1% variance) + PC4 (explaining 6.1% variance) highlights the
proportion of transcriptomic shift induced by the treatments in septic male mice towards
septic females. The term `solvent' here represents the septic male mice treated with solvent.
energy, glucose metabolic processes were downregulated. Apart from glucose
metabolism, metabolism of other energy precursors such as acetyl-CoA, alpha-amino
acids and fatty acids were evidently downregulated. The synthesis of energy
precursors and break down of complex organic molecules are mainly carried out by
mechanisms of oxidation-reduction process that result in the synthesis of reactive
oxygen species. This cascade was downregulated in the liver of septic females.
Despite the downregulation of the energy metabolism, the cell death mechanisms
were not upregulated, on contrary, gene sets such as apoptic process and the
programmed cell death were downregulated. There were a plethora of gene sets
ascribed to response to various stimuli, such as organic substances, lipids,
oxygen-containing compounds etc. being downregulated indicating an overall state
of desensitization of hepatocytes. Among the upregulated gene sets in septic females
were the transcription and translation associated processes such as RNA metabolic
processes, RNA splicing, RNA processing and translation initiation. At most ve
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top signicant gene sets from each category are given below in Table 4.14 and Table
4.15. In summary, septic female mice downregulated immune response, redox
processes, energy processes and cell death mechanisms in liver.
Table 4.14: Enriched sets of upregulated genes in the liver of septic females
* Gene set ID
Adjusted
p-value
Sig.
genes
AP amide biosynthetic process GO:0043604 2.63E-07 40
AP
organonitrogen compound biosynthetic
process
GO:1901566 8.46E-06 52
AP cellular component biogenesis GO:0044085 6.22E-03 73
AP ribonucleoprotein complex biogenesis GO:0022613 8.55E-03 20
CP
ER-associated ubiquitin-dependent protein
catabolic process
GO:0030433 1.94E-04 9
CP cellular macromolecule catabolic process GO:0044265 1.63E-03 33
CP macromolecule catabolic process GO:0009057 1.84E-03 38
CP catabolic process GO:0009056 3.35E-03 54
CP cellular catabolic process GO:0044248 3.57E-03 46
HR cellular response to gonadotropin stimulus GO:0071371 1.57E-03 5
HR response to thyroid hormone GO:0097066 3.38E-03 5
HR
cellular response to follicle-stimulating
hormone stimulus
GO:0071372 5.20E-03 4
HR response to hormone GO:0009725 1.00E-02 31
MP cellular amide metabolic process GO:0043603 3.67E-07 46
MP cellular lipid metabolic process GO:0044255 7.82E-05 39
MP fatty acid metabolic process GO:0006631 4.41E-04 21
MP organonitrogen compound metabolic process GO:1901564 5.32E-04 69
MP monocarboxylic acid metabolic process GO:0032787 1.08E-03 26
SR cellular response to stress GO:0033554 4.60E-04 57
SR response to endoplasmic reticulum stress GO:0034976 1.01E-03 15
TT RNA processing GO:0006396 8.96E-08 42
TT translation GO:0006412 7.80E-06 34
TT RNA splicing GO:0008380 2.11E-05 23
TT RNA export from nucleus GO:0006405 4.85E-04 9
TT regulation of translational initiation GO:0006446 2.31E-03 8
MC protein N-linked glycosylation via asparagine GO:0018279 1.11E-03 6
MC single-organism catabolic process GO:0044712 9.73E-03 28
* Categories: AP - Anabolic processes, CP - Catabolic processes, HR - Hormonal response,
MP - Metabolic processes, SR - Stress response, TT - Transcription and translation, MC -
Miscellaneous
Table 4.15: Enriched sets of downregulated genes in the liver of septic females
* Gene set ID
Adjusted
p-value
Sig.
genes
AP lipid biosynthetic process GO:0008610 2.50E-09 31
AP carboxylic acid biosynthetic process GO:0046394 1.53E-05 16
AP regulation of gluconeogenesis GO:0006111 1.27E-04 7
Continued on next page
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Table 4.15 { Continued from previous page
* Gene set ID
Adjusted
p-value
Sig.
genes
AP protein oligomerization GO:0051259 1.44E-03 19
AP
organonitrogen compound biosynthetic
process
GO:1901566 6.59E-03 36
CD cell death GO:0008219 1.07E-04 52
CD programmed cell death GO:0012501 4.07E-04 48
CD apoptotic process GO:0006915 1.06E-03 46
CD regulation of cell death GO:0010941 1.06E-03 41
CD positive regulation of apoptotic process GO:0043065 3.44E-03 19
CP organic acid catabolic process GO:0016054 4.47E-14 24
CP carboxylic acid catabolic process GO:0046395 2.59E-13 22
CP cellular amino acid catabolic process GO:0009063 2.33E-10 13
CP
fatty acid beta-oxidation using acyl-CoA
dehydrogenase
GO:0033539 3.00E-03 4
CP nucleobase catabolic process GO:0046113 3.02E-03 3
EM
generation of precursor metabolites and
energy
GO:0006091 7.64E-08 22
EM hexose metabolic process GO:0019318 1.31E-07 18
EM glucose metabolic process GO:0006006 2.65E-06 15
EM cellular respiration GO:0045333 2.85E-04 11
EM aerobic respiration GO:0009060 2.87E-04 8
GR liver development GO:0001889 2.46E-05 12
GR regulation of centromere complex assembly GO:0090230 2.27E-04 3
GR lipid modication GO:0030258 4.00E-04 12
GR aging GO:0007568 3.83E-03 13
HR steroid biosynthetic process GO:0006694 4.06E-07 14
HR response to peptide hormone GO:0043434 2.02E-05 23
HR response to glucocorticoid GO:0051384 3.56E-04 11
HR response to insulin GO:0032868 5.69E-04 16
HR estrogen biosynthetic process GO:0006703 1.91E-03 3
HS chemical homeostasis GO:0048878 4.45E-06 38
HS cellular iron ion homeostasis GO:0006879 9.32E-05 7
HS cellular transition metal ion homeostasis GO:0046916 1.10E-04 9
HS cation homeostasis GO:0055080 4.18E-03 21
HS cellular cation homeostasis GO:0030003 4.33E-03 19
IR response to interleukin-1 GO:0070555 1.89E-04 10
IR response to molecule of bacterial origin GO:0002237 7.06E-04 16
IR cellular response to lipopolysaccharide GO:0071222 1.19E-03 11
IR immune system process GO:0002376 2.76E-03 54
IR acute-phase response GO:0006953 5.61E-03 5
MP organic acid metabolic process GO:0006082 1.76E-24 64
MP
organic hydroxy compound metabolic
process
GO:1901615 1.42E-09 26
MP acetyl-CoA metabolic process GO:0006084 1.07E-04 6
MP
cellular modied amino acid metabolic
process
GO:0006575 4.35E-04 10
MP alpha-amino acid metabolic process GO:1901605 4.75E-04 12
OS oxidation-reduction process GO:0055114 9.40E-04 79
OS reactive oxygen species metabolic process GO:0072593 9.75E-04 15
Continued on next page
65
Chapter 4 { Results
Table 4.15 { Continued from previous page
* Gene set ID
Adjusted
p-value
Sig.
genes
OS
cellular response to oxygen-containing
compound
GO:1901701 1.15E-03 34
OS
regulation of reactive oxygen species
metabolic process
GO:2000377 2.36E-03 11
RS response to organonitrogen compound GO:0010243 1.90E-07 35
RS response to external stimulus GO:0009605 2.49E-06 63
RS response to lipid GO:0033993 1.34E-05 35
RS response to oxygen-containing compound GO:1901700 5.39E-05 49
RS response to endogenous stimulus GO:0009719 1.77E-04 47
SP
positive regulation of intracellular signal
transduction
GO:1902533 2.54E-04 30
SP regulation of biological quality GO:0065008 9.84E-04 76
SP intracellular signal transduction GO:0035556 1.94E-03 56
SP positive regulation of cell communication GO:0010647 3.23E-03 39
SP protein kinase B signaling GO:0043491 4.22E-03 10
SR response to wounding GO:0009611 2.88E-05 23
TR regulation of cellular localization GO:0060341 2.11E-03 27
MC
single-organism carbohydrate metabolic
process
GO:0044723 5.93E-08 26
MC single-organism catabolic process GO:0044712 4.35E-04 45
MC macromolecular complex assembly GO:0065003 2.58E-03 39
MC protein complex assembly GO:0006461 2.81E-03 32
MC gland development GO:0048732 3.45E-03 20
* Categories: AP - Anabolic processes, CD - cell death, CP - Catabolic processes, EM -
Energy metabolism, GR - Growth response, HR - Hormonal response, HS - Homeostasis,
IR - Immune response, MP - Metabolic processes, OS - Oxidative stress, RS - Response to
stimuli, SP - Signaling processes, SR - Stress response, TR - Transport, TT - Transcription
and translation, MC - Miscellaneous
4.3.3 Atraric acid treatment induces female-like response by
downregulation of immune response, oxidative stress
and cell death in the liver of septic male mice
The signicant dierentially expressed genes that overlapped between the
comparison of AA treated septic male versus solvent treated septic male and solvent
treated septic female versus solvent treated septic male in the same up- or
down-regulated fashion were referred to as codirectional genes. These were 157 up-
and 107 down-regulated genes essentially describing the female-like response of the
AA treatment. Female-like upregulated genes were not enriched among any gene
sets, however, downregulated genes were found associated with immune response,
oxidative stress and cell death mechanisms. The immune response was restricted to
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the gene sets of innate immunity such as response to lipopolysaccharide and response
to pro-inammatory cytokines such as interleukin-1 (IL-1) and interleukin-6 (IL-6).
The redox processes were not downregulated however the associated reactive oxygen
species metabolic process was present. Interestingly, by AA treatment, liver of male
mice also downregulated programmed cell death in female-like fashion. The
treatment also induced the desensitization of the hepatocytes by downregulation of
response to various external stimuli such as organic substances, endogenous stimuli,
lipids, oxygen-containing compounds etc. Table 4.16 lists the ve topmost signicant
gene sets from each category. In summary, the AA treatment to septic male mice
induced a female-like transcriptomic response in the form of downregulation of
immune response, oxidative stress and cell death mechanisms in liver.
Table 4.16: Enriched sets of female-like downregulated genes in the liver of AA treated
male septic mice
* Gene set ID
Adjusted
p-value
Sig.
genes
CD cell death GO:0008219 9.62E-06 25
CD regulation of cell death GO:0010941 1.30E-04 20
CD programmed cell death GO:0012501 1.35E-04 22
CD apoptotic process GO:0006915 3.42E-04 21
CD positive regulation of apoptotic process GO:0043065 3.30E-03 10
CP positive regulation of catabolic process GO:0009896 5.54E-05 9
CP
positive regulation of protein catabolic
process
GO:0045732 4.48E-04 7
CP
positive regulation of cellular catabolic
process
GO:0031331 6.39E-04 7
CP organic substance catabolic process GO:1901575 9.60E-04 20
CP catabolic process GO:0009056 9.90E-04 20
GR regulation of cellular component movement GO:0051270 1.09E-03 13
GR cell migration GO:0016477 1.33E-03 17
GR aging GO:0007568 1.89E-03 8
GR regulation of cell shape GO:0008360 8.49E-03 5
HR response to hormone GO:0009725 2.91E-03 12
HS myeloid cell homeostasis GO:0002262 9.09E-03 5
IR immune system process GO:0002376 4.68E-05 26
IR cellular response to lipopolysaccharide GO:0071222 9.11E-04 9
IR response to interleukin-1 GO:0070555 1.03E-03 6
IR cellular response to interleukin-6 GO:0071354 4.69E-03 3
IR chemokine-mediated signaling pathway GO:0070098 6.74E-03 4
MP
positive regulation of macromolecule
metabolic process
GO:0010604 1.41E-05 31
MP
positive regulation of cellular metabolic
process
GO:0031325 8.75E-04 27
OS
cellular response to oxygen-containing
compound
GO:1901701 8.46E-05 17
Continued on next page
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Table 4.16 { Continued from previous page
* Gene set ID
Adjusted
p-value
Sig.
genes
OS
regulation of reactive oxygen species
metabolic process
GO:2000377 1.08E-03 6
OS reactive oxygen species metabolic process GO:0072593 1.65E-03 7
RS response to external stimulus GO:0009605 2.45E-05 26
RS response to oxygen-containing compound GO:1901700 1.05E-04 20
RS response to lipid GO:0033993 1.39E-04 15
RS cellular response to organic cyclic compound GO:0071407 5.16E-04 11
RS response to organic cyclic compound GO:0014070 6.63E-04 15
SR regulation of response to stress GO:0080134 6.05E-04 16
TR movement of cell or subcellular component GO:0006928 2.22E-04 21
TR positive regulation of protein transport GO:0051222 5.27E-03 9
TT positive regulation of gene expression GO:0010628 2.03E-03 19
MC locomotion GO:0040011 6.47E-05 21
MC muscle cell cellular homeostasis GO:0046716 1.27E-03 3
MC
hematopoietic or lymphoid organ
development
GO:0048534 3.25E-03 13
MC ossication GO:0001503 6.40E-03 8
MC blood vessel development GO:0001568 9.49E-03 10
* Categories: CD - cell death, CP - Catabolic processes, GR - Growth response, HR -
Hormonal response, HS - Homeostasis, IR - Immune response, MP - Metabolic processes,
OS - Oxidative stress, RS - Response to stimuli, SP - Signaling processes, SR - Stress
response, TR - Transport, TT - Transcription and translation, MC - Miscellaneous
4.3.4 Flutamide treatment induces female-like response by
downregulation of cell death mechanisms in the liver
of septic male mice
The codirectional genes were identied for Flu treatment similarly as
described in the above section. These were 113 up- and 112 down-regulated genes
those essentially described the female-like response of Flu treatment. The
female-like upregulated genes were solely enriched in the category of translation and
amide biosynthesis. Interestingly, the Flu treatment also downregulated the cell
death and programmed cell death gene sets in female-like manner. Signicant gene
sets from each category are given below in Table 4.17 and Table 4.18. In summary,
the Flutamide treatment to septic male mice induced a female-like transcriptomic
response in the form of downregulation of cell death mechanisms in the liver.
68
Chapter 4 { Results
Table 4.17: Enriched sets of female-like upregulated genes in the liver of Flu treated
male septic mice
* Gene set ID
Adjusted
p-value
Sig.
genes
AP amide biosynthetic process GO:0043604 1.97E-03 14
MP cellular amide metabolic process GO:0043603 1.81E-03 16
TT translation GO:0006412 2.22E-03 13
* Categories: AP - Anabolic processes, MP - Metabolic processes, TT - Transcription and
translation
Table 4.18: Enriched sets of female-like downregulated genes in the liver of Flu treated
male septic mice
* Gene set ID
Adjusted
p-value
Sig.
genes
CD cell death GO:0008219 1.02E-03 23
CD programmed cell death GO:0012501 3.85E-03 21
CP catabolic process GO:0009056 8.35E-06 25
CP organic substance catabolic process GO:1901575 2.44E-04 22
CP cellular catabolic process GO:0044248 1.23E-05 22
MP cellular lipid metabolic process GO:0044255 3.89E-03 14
MC ossication GO:0001503 7.12E-03 9
* Categories: CD - Cell death, CP - Catabolic processes, MP - Metabolic processes, MC -
Miscellaneous
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5.1 IFN/IL-10 acts as a theranostic marker for
stratication of hydrocortisone therapy in
patients with septic shock
The clinical community is divided regarding the use of `moderate-dose'
hydrocortisone (HC) to patients with septic shock. Though faster shock resolution
is consistently reported in a meta-analysis [Annane et al., 2009] and in ADRENAL
[Venkatesh et al., 2018] trial, the survival benet with HC treatment was
demonstrated only in two French randomized controlled trials, when administered
together with udrocortisone ([Annane et al., 2002] and APROCCHSS [Annane
et al., 2018]). However, survival advantage with HC could not be replicated in
CORTICUS [Sprung et al., 2008] and ADRENAL [Venkatesh et al., 2018] trails.
Possible explanations for this disparity include dierences in the patient population
with a two-fold higher risk of death in the French control group (of [Annane et al.,
2009]) compared to CORTICUS (61% versus 31%, respectively), and an increase in
superinfections, including new episodes of sepsis or septic shock recorded with
corticosteroid administration in the CORTICUS trial. Considering these observed
disparities and dierences in outcome, it was hypothesized that a subset of patients
might benet from the HC treatment while others may get harmed. With this aim
to identify these subsets, a machine learning based study was performed.
Starting with a larger panel of predictors from septic shock patients treated with
HC or placebo in CORTICUS, the ratio of serum IFN and IL-10 was identied as the
promising new marker for HC treatment decision (odds ratio of 3.03, P=0.031). The
treatment decision was formulated as: HC if the ratio is low and no HC treatment if
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the ratio is high. The panel predictor included the patient demographic data, clinical
features and serum blood cytokine measurements from 83 patients. The rule was
further validated by applying the marker and threshold to three unseen datasets. For
CORTICUS, the cuto value for deciding if the ratio of IFN/IL-10 is low or high
was found to be the 39.8 percentile (patients which IFN/IL-10 ratio ranked among
the rst 39.8% patients were denoted \low ratio patients", the others \high ratio
patients"). As in particular the survival rate of the HSSG cohort was very dierent
to CORTICUS, this value needed to be adjusted by a calibration curve calculated from
the CORTICUS dataset mimicking higher death rates in CORTICUS by weighting
non-survived patients higher. The serum cytokine measurements were performed
by dierent assays, in dierent labs and at dierent times (HSSG: own data from
2018, CORTICUS: data from the publication of 2009, SISPCT: own data from 2017,
Crossover study: data from the publication in 2003). Applying successfully the rule
across dierently generated data suggests this marker to be generic and relatively
robust.
The functional implications of low and high IFN/IL-10 ratios were elucidated
by performing blood culture assays. The ratio was observed to be negatively
associated with the pathogen load in ex vivo blood culture experiments. This was
supported by the clinical data from Matera et al. in their study regarding critically
ill patients with bacteremia (higher bacterial load) and without bacteremia (none or
non-detectable bacterial load). Critically ill patients with bacteremia showed a
lower ratio compared to those without bacteremia [Matera et al., 2013].
Metabolically, elevated serum lactate indicates the severity of cellular disturbances
[Singer et al., 2016] and is associated with poor outcome [Casserly et al., 2015].
Patients with low IFN/IL-10 showed high serum lactate. Furthermore, by
stratifying patients in compliance with the proposed decision rule, a considerable
decrease was observed over time in serum lactate specically in the group of
patients which were treated in compliance with the theranostic marker. The
recovery from septic shock is indicated by reduced norepinephrine requirement
[Dellinger et al., 2013]. Indeed, the patients treated in compliance with the
proposed decision rule showed a signicant rate of decrease in norepinephrine
consumption indicating a better recovery of these patients.
IFN has been consistently documented to activate cells of adaptive immunity
[Schoenborn and Wilson, 2007] and IL-10 as a suppressor of innate immune
responses and inammation [Sabat et al., 2010, Kuhn et al., 1993]. Accordingly,
high IFN/IL-10 reects increased activated adaptive and innate immunity.
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Transcriptomic proles of patients with high ratios compared to patients with low
ratios comprised of upregulated genes coding for the immune system and,
surprisingly, for proliferation and cell cycle. Comparing this list to gene signatures
of activated T-cells and macrophages associates upregulation of the immune
response with activated macrophages, while upregulation of proliferation/cell cycle
rather with T-cells. Together, this may reect a recovery of immune cells in which
corticosteroid treatment may slow down this process. In turn, low IFN/IL-10 may
indicate the opposite scenario of a strong suppression of innate immunity and low
activation of cells of adaptive immunity. Indeed, blood challenged with bacterial
fragments ex vivo displayed low IFN/IL-10 at high loads and vice versa.
Transferring these observations to septic shock patients with low IFN/IL-10, it
reects that HC treatment yielded a better outcome in HC-responders because HC
may have allowed the highly loaded immune system more pace for recovery. This is
evidenced when regarding time lapse expression proles, as particularly in the
leukocytes of the responders, genes for immunity and proliferation were
upregulated, quite like the proles of patients with initial high IFN/IL-10.
Notably, this included all three members of the butyrophilin subfamily 3. The
expression of these genes was reported to correlate with the severity of sepsis
negatively [Andreu-Ballester et al., 2013]. The genes encode receptors of T-cells
and have been associated with tuberculosis protection and early IFN production
[Chen, 2016]. This is evidenced, as written above, by the reduction of serum lactate
and norepinephrine requirement as an indicator of recovery, particularly in these
patients.
The concern about the side eects of corticosteroids such as infections in
patients with less severe septic shock stipulated more restrictive recommendations
by the Surviving Sepsis Campaign. HC application is currently recommended for
patients not responding to adequate uid resuscitation and vasopressor therapy
[Dellinger et al., 2008, Dellinger et al., 2013]. It seems intuitively promising to
include an immune biomarker, such as IFN/IL-10 reecting the status of the
patients' immune system. Consistent with this concept, Bentzer et al. performed a
secondary analysis of the VASST trial investigating corticosteroid treated versus
non-treated (only vasopressin or norepinephrine vasopressors) patients. A signature
of three cytokines (IL3, IL6, CCL4) was identied suggesting a response to
corticosteroid treatment [Bentzer et al., 2016]. However, these ndings were based
on a study which was not controlled, randomized or blinded according to
corticosteroid treatment. Further, the study neither distinguished between the
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vasopressin and norepinephrine treatment nor investigated on how these three
cytokines interact with corticosteroid treatment. In turn, based on transcriptomic
investigations, this thesis provides molecular reasoning that the identied ratio of
serum cytokines IFN and IL-10 seems to stratify corticosteroid treatment for
recovery of peripheral immune cells.
Limitations and strengths
The relatively small sample sizes along with the high dimensional data sets
obtained imply that these results must be interpreted with caution. A further
limitation of this study was that the use of corticosteroids was not randomized in
the HSSG and the SISPCT study. The strengths or limitation of this study was
that the validation of the marker based on serum cytokine data was measured very
dierently to CORTICUS suggesting the marker does not depend on a certain
platform of the assay. Strengths of this study were that (i) the well-phenotyped
cohorts of patients with septic shock were used, (ii) the marker showed very similar
results across all studies, and (iii) not only the marker showed the potential clinical
relevance but also provided a functional reasoning why this may support HC
application by investigating ex vivo blood culture experiments.
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5.2 Temporal progression of gene regulation of
leukocytes explains gender dimorphism of
critically ill patients after trauma
Previous clinical trials showed that female (in their premenopausal phase)
compared to male trauma patients are better protected from organ failure, show
fewer complications, better tolerate critical trauma and develop less severe organ
failure. As dierences in gene regulation of healthy individuals have been described
[Klein and Flanagan, 2016, Tarnopolsky and Ruby, 2001, Wu and O'Sullivan,
2011, Green et al., 1984], in this thesis it was hypothesized that gender dimorphism
is also prominent in the gene regulation of peripheral leukocytes of the critically ill
and may explain the better clinical course of female patients. As a case study,
critically ill patients after blunt trauma were investigated. A statistical framework
synchronizing the transcription proles based on the severity of the patients was
developed which enabled the tracking of the dierences in male and female patients
before, at, and after the most acute phase of organ dysfunction. The analytical
approach detected a very divergent regulation of male and female patients. The
main ndings were validated by a second, independent dataset of transcription
proles from peripheral leukocytes of patients with severe burn injury.
In the early pre-acute phase, leukocytes of female patients showed a stronger
innate immune response at the transcriptional level. Particularly the upregulation
of NF-B transcription activity and the ERK1-ERK2 signaling cascade. The role of
NF-B and ERK1-ERK2 signaling are well described in the survival, activation and
dierentiation of innate immune cells independent of gender [Busca et al., 2016, Liu
et al., 2017]. Distinct gender dimorphism had been described for components of
innate immunity such as higher eciency of antigen presenting cells (APCs), higher
activation and phagocytotic activity of macrophages and neutrophils of female
patients [Klein and Flanagan, 2016]. This supports the observed ndings on a
systems-view. In addition, the upregulation of genes for higher myeloid dendritic
cell dierentiation and neutrophil chemotaxis was observed in female patients.
Myeloid dendritic cells are the bridge linking innate and adaptive immunity. They
comprise a heterogeneous population of cells presenting antigens to T-cells
[Chistiakov et al., 2015]. During the same phase, IL-7 mediated signaling was
observed to be upregulated in female patients. IL-7 signaling has been extensively
studied in the context of survival and dierentiation of B-cells, and proliferation of
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B- and T-cells [Sammicheli et al., 2012, Corfe and Paige, 2012, Guimond et al.,
2009]. Immunotherapy by application of IL-7 has been shown to enhance the
immune response in patients with limited nave T-cells [Unsinger et al.,
2010, El-Kassar et al., 2012, Tuckett et al., 2014]. Furthermore, high levels of IL-7
have been reported to aect the selection of the T- versus the B-cell lineage
[El-Kassar et al., 2012]. These early triggers may support the recovery of adaptive
immunity which was found to be upregulated in female patients later in the late
post-acute phase.
During the pre-acute phase, the upregulation of early wound healing and
recovery processes was observed in female patients. Better wound healing in
premenopausal females has been reported in a few studies before [Jorgensen et al.,
2002, Ashcroft and Ashworth, 2003, Gilliver et al., 2008]. Wound healing is a highly
organized process involving several characteristic overlapping steps including skin
and vessel integrity restoration, inammation for attracting leukocytes, proliferation
to diminish the lesioned tissue area and remodelling of the extra cellular matrix
[Gonzalez et al., 2016]. Indeed, in the pre-acute phase, leukocytes of female patients
showed upregulated processes associated with restoring tissue and vessel integrity.
These included upregulation of platelet activation/degranulation and blood
coagulation to restrict losing blood. The second stage of wound healing is
characterized by localized swelling and clearance of damaged cells and pathogens
from the wound area. In line, female patients showed an upregulation of genes for
leukocyte migration and regulation of phagocytosis. Higher activation and
phagocytotic activity of macrophages and neutrophils have been previously reported
in females [Klein and Flanagan, 2016]. Upregulation of the MAPK cascade and
required protein phosphorylation gene sets was observed in female patients, which
play a predominant role for cell proliferation, cell-cell adhesion and growth during
early wound healing [Thuraisingam et al., 2010]. It is reasonable that, at the
transcriptomic level, healing processes are initiated before the acute phase. These
processes may form the functional basis to initiate wound healing processes.
Upregulation of these processes was followed by upregulated gene sets related to cell
growth and development at the acute phase. Leukocytes of female patients showed
an upregulation of IL-1 signaling. The family of IL-1 cytokines activates the innate
immune system and also supports the activation and proliferation of T-cells [Sims
and Smith, 2010]. In line, an upregulation of the adaptive immune system and
T-cell growth was observed in the late post-acute phase.
The dierential regulation of energy metabolism and housekeeping processes
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covered almost two-third of the identied sex-specic gene sets. From the pre-acute
to the acute phase, leukocytes of female patients downregulated energy metabolism
and, in particular, oxidative phosphorylation. The downregulation was observed for
ATP producing and consuming processes. Surprisingly, peripheral leukocytes of
female patients may sustain a limited metabolism by such downregulation without
being driven into apoptosis, as upregulation of cell death associated processes was
not observed compared to male patients.
During the pre-acute phases of increasing multiple organ failure, a reduced energy
production may be advantageous by limiting the production of reactive oxygen species
(ROS). It was reported that cells of females are less exposed to oxidative stress in
healthy conditions. Ide et al. observed a lower abundance of in vivo biomarkers
for oxidative stress in premenopausal women [Ide et al., 2002]. In an animal model,
lower oxidative stress was observed [Barp et al., 2002], and ROS production was
lower in human umbilical endothelial cells of female compared to male [Zhang and
Lingappan, 2017]. Hence, higher exposure to oxidative stress may be an intrinsic
risk factor for male individuals when getting critically ill. In his review about the
discrepancy between the need for energy and the potential risk of cell damage when
producing energy, Mervyn Singer describes that a hallmark of survivors of sepsis is
to better preserve ATP and mitochondrial functions [Singer, 2014]. He suggests that
in these patients, cells may enter a \hibernating state in the face of overwhelming
inammation". Our observation supports this as particularly in the critical pre-
acute phases, as a distinct downregulation of these energy producing and consuming
processes in the leukocytes of female patients was observed. As described above, these
female patients showed a better recovery, as, despite no dierences between the sexes
in the injury score (AIS) at baseline, the MOF score was higher in male patients at
and after the acute phase. Taken together, the leukocyte transcriptomic response to
trauma point to a better bioenergetic tolerance and oxidative damage resistance in
female patients.
The gene sets of the adaptive immune response were distinctively higher
expressed in leukocytes of female, compared to male patients during the late
post-acute phase, and also compared to healthy controls. Additionally, female
patients showed a distinct upregulation of IL-4 production. The presence of IL-4
during the response of nave T helper cells has been shown in the development of
Th2 cells [Zhu et al., 2010]. Interestingly, negative regulation of type I interferon
production was also upregulated in female patients. Type I IFNs are known to be
important for host defence against viruses. However, in vivo studies have also
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identied their immune suppressive mechanisms [McNab et al., 2015], hence low
levels for its negative regulation may support the immune recovery. This suggests
that gene regulation in female, but not in male patients, pave the way for better
recovery of the adaptive immune system at the later stages.
Limitations and strengths
There are certain limitations of this study. The patients with multiple acute
phases that were days apart were not included in the study due to their limited
number of such patients and the availability of their transcriptome data. The primary
goal of this study was to identify sex-based transcriptomic dierences in critically ill
patients undergoing MOF, using the study of \Inammation and the Host Response
to Injury (Trauma)" as a case study. To fully understand sex-based dierences in
the complicated recovery, a dierent stratication approach with a higher number of
time-resolved transcription proles are required. The strength of the study lies in
the fact that it not only highlights the sex-based dierences in the critically injured
patients but also demonstrates that these dierences vary as the disease progresses,
which has not been shown before. Also, the identied dierences could be replicated
in another independent cohort of critically injured patients irrespective of the type of
injuries.
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5.3 The anti-androgenic and pro-estrogenic
treatment potentially enhances tolerance in
the liver of septic male mice as a defense
strategy
The previous section described the sex-based dierences in leukocyte expression
of critically ill patients. It demonstrated that the premenopausal female patients show
a transcriptomic prole that reason their better molecular response and reduced organ
failure scores despite having a similar degree of injury. This third study of the thesis
was dedicated to understanding the transcriptomic response of septic male mice upon
treatment with drugs that are known to combine anti-androgenic and pro-estrogenic
eects. These drugs specically include Flutamide, an FDA approved synthetic drug
prescribed primarily for the treatment of prostate cancer and partly as a component of
feminizing hormone therapy for transgender women [Dahl et al., 2015], and a naturally
occurring non-steroidal anti-androgenic and potent pro-estrogenic drug called Atraric
acid (AA).
The gender dimorphism between septic pre-estrus female mice and septic male
mice has been shown in the PCI [Roll, 2015] as well as CLP [Zellweger et al., 1997]
sepsis models. As reported by Dr. Roll, in the PCI sepsis model, the dierence in
mortality was compelling, since 80% of the female mice survived 72 hours post-PCI
but, all male mice died at latest as 28 hours. By Dr. Roll, the rescue of septic male
mice was shown to be enabled by treatment with either AA or Flu. In Addition,
Dr. Roll showed that neither the pure AR inhibition nor the pure ER activation
alone was enough for the signicant improvement of survival rates in male mice.
However, a marginally benecial eect of solely ER induction has also been shown
to improve the sepsis outcome partly [Angele et al., 1997, Raju and Chaudry, 2008].
The manifold improvement has been demonstrated by the treatment of Flu or AA
resulting in signicantly enhanced survival (20-25%) in males, suggesting that both
modes of action together were more eective: the inhibition of AR and the activation
of ER. At 10 hours post-PCI, also the time point when gene expression was measured,
all animals showed a comparable severity score, thereby indicating that complete
prevention of infection was not the reason for the gender dimorphism [Roll, 2015].
However, cytokine levels (IL-6, IL-10, TNF-, MCP-1, IFN-, IL-12p70) measured
in blood serum and liver tissue, together with liver function parameters (Lactate
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dehydrogenase, Creatinine, Aspartate transaminase, Bilirubin) were failing to provide
molecular insights into the survival advantages. Hence, to gain further insights into
the inuence of AA and Flu on septic male mice and the gender dimorphism at
molecular levels, liver transcriptome proling was carried out.
In this thesis, the analysis of the liver transcriptome proles was performed. PCA
analysis was conducted to study the eect of gender and treatment on a systems
view. PCA showed a distinct transcriptomic separation between septic male and
female samples. Notably, PCA also revealed a transcriptomic shift toward females
upon treatment with AA or Flu, which was further rened by taking the combination
of PCs. The marked shift indicates that the treatments have induced female-like
transcriptomic changes that may have contributed to the rescue of male septic mice.
The gender dimorphic inuence on the transcriptome of the liver was studied
using dierential gene expression analysis. Anatomically, the liver consists of
70-80% of the hepatocytes, 14-17% of cellular components of extracellular spaces
and 5-6% of non-parenchymal cells. The non-parenchymal cells consist of a diverse
set of cells, including 45% liver sinusoidal endothelial cells, 33% Kuper cells, and
22% hepatic stellate cells [Bogdanos et al., 2013]. The liver facilitates a tolerance
rather than immunoreactivity, which protects the host from an antigenic overload of
dietary components and drugs derived from the gut [Bogdanos et al., 2013]. A
disease such as sepsis is known to exaggerate the antigenic overload by bringing a
milieu of pathogen-associated molecular patterns (PAMPs), damage-associated
molecular patterns (DAMPs) and organic/inorganic toxins into the circulation and
especially to the liver [Hotchkiss et al., 2016]. During sepsis, the liver of female mice
showed overall desensitization to various receptor stimuli by downregulating their
response pathways. Receptor desensitization has been known to cause temporary
tolerance allowing the cell to protect themselves from prolonged or overstimulation
by ligands [Arey, 2014]. In line, the desensitization was observed in female mice for
a variety of molecules such as lipids, oxygen-containing compounds and cytokines,
which in this context are mainly contributed by the inammatory cascades and
associated damage. Together with other biotic and abiotic stimuli, female mice also
repressed the response to immune mediators such as IL-1, and the molecules of
bacterial origin such as LPS. Such suppression of immune cascades possibly has
resulted in the overall downregulation of the acute phase response in female mice.
The inhibition of the IL-1 cascade might have contributed in favor of females, as the
therapeutic inhibition of IL-1 by receptor antagonists (anakinra) has been shown to
be eective in a subset of sepsis patients [Shakoory et al., 2016].
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Female mice have also shown downregulation of energy metabolism. This
involved the downregulation of energy synthesis by cellular respiration along with
the downregulation of processes involved in the generation of energy precursors such
as acetyl-CoA and glucose metabolism. A typical consequence of energy production
is the production of Reactive Oxygen Species (ROS) by a series of
oxidation-reduction (Redox) processes. In septic conditions, the rate of ROS
synthesis has been reported to increase manifold [Galley, 2011]. However, the redox
processes were downregulated in female mice suggesting that reduced energy
production might have contributed to less oxidative stress by limiting ROS
production. As discussed in the previous section several studies have demonstrated
that females are less exposed to oxidative stress in healthy conditions. Hence, higher
exposure to oxidative stress may be an intrinsic risk factor for male sex.
Surprisingly, such reduced energy metabolism in the liver of female mice was
sustainable without being driven into apoptosis. On the contrary, cell death
mechanisms were downregulated compared to male mice.
The transcriptomic response of septic liver of female mice can be correlated to
the leukocyte transcriptomic response of female trauma patients during the
pre-acute to acute phase to some extent. In both scenarios, processes associated
with energy metabolism, generation of ROS, and oxidation-reduction were
downregulated. Despite the reduced energy metabolism, the cell death processes
were either comparable or downregulated compared to males. However, the immune
response was observed to be the opposite. This supports the notion of the immune
response being a double-edged sword [Ashida et al., 2011], where, the leukocytes
from female patients showed higher innate and adaptive response directed towards
pathogen clearance, while liver of female mice showed a repressed innate immune
response reducing the organ damage at the site.
In summary, liver of female septic mice showed enhanced tolerance at the
transcriptomic level, where the tolerance was dened as protection from antigenic
overload by receptor desensitization, reduced immunoreactivity and inhibition of
cell death in liver [Bogdanos et al., 2013].
The female-like response of the AA treatment was studied by identifying the
signicantly expressed co-directional genes between the treatment and female mice
compared to solvent treated males. In a female-like manner, AA also induced the
desensitization of the receptor response to external stimuli including the response
elicited by IL-1, IL-6, and LPS. The role of IL-1 has been extensively studied and
its persistent increase during the rst seven days from admission is associated with
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increased death in septic patients [Mera et al., 2011]. Similarly, IL-6, a pleiotropic
cytokine that functions as both pro- and anti-inammatory has been associated
with the development of sepsis [Gouel-Cheron et al., 2012] and with the highest risk
of death in patients with sepsis [Kellum et al., 2007]. The reduced response to these
cytokines may have delivered the survival benets. As observed in female mice, the
treatment with AA did not induce downregulation of energy metabolism, nor it
downregulated the oxidation-reduction processes. However, ROS metabolic
processes were present and downregulated. The lower levels of ROS may refrain
from accelerating the organ dysfunction. The female-like eects of AA also included
downregulation of cell death mechanisms. In summary, as observed in females, the
treatment of AA also included protection from antigenic overload by receptor
desensitization, reduced immunoreactivity and inhibition of cell death, thereby
possibly enhancing the tolerance in the liver.
Despite having a similar degree of survival benets by AA treatment, female-like
eects of Flu treatment were limited to the downregulation of cell death
mechanisms, catabolic processes and the upregulation of translation processes.
Female-like co-directional genes were similar in both treatments (AA: 157 up, 107
down; Flu: 113 up, 112 down), yet a lower number of signicant gene sets were
identied in the case of Flu treatment. The limited number of gene sets may
indicate broader functional consequences of Flu treatment as opposed to a few
highly specic functions being aected. The only commonality between the
female-like eects of AA and Flu treatments was the downregulation of cell death
mechanisms. The receptor desensitization and reduced immunoreactivity were not
observed at the studied time point of 10 hours, however, Kan et al. identied that
Flu treatment reduced cytokine/chemokine production (IL-6, TNF-, MCP-1),
oxidative stress, and hepatocyte apoptosis at 2 hours after trauma-hemorrhage [Kan
et al., 2008]. Although AA and Flu both induce anti-androgenic and pro-estrogenic
eects their kinetics of bringing transcriptomic changes may vary. Hence,
time-resolved transcriptome proles are needed to explore their female-like eects in
greater depth. In summary, the observed transcriptomic changes strongly suggest
that the survival advantage coming from these treatments could be from the
enhanced tolerance as a defense strategy.
Limitations and strengths
The limitation of this study was the lower sample size; hence the observations
are needed to be interpreted with caution. Additionally, as pointed out in the previous
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section of this thesis that sex-dierences vary as the disease progresses, more than one
time point may be necessary to decipher the benecial roles of the treatments in more
details. The strength of this study lies in the fact that the eects of the treatments
and the gender dierences are studied in an animal model where heterogeneity is well
controlled as opposed to a patient cohort.
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Aim of this thesis was to nd clinico-transcriptomics approaches to improve
outcome in critically ill patients with cortico-and sex-steroids. Two
clinico-transcriptomics approaches were developed, and their ndings were validated
on unseen datasets. Validation of any new sepsis-related nding is crucial given the
heterogeneity in septic patients. Many seemingly promising treatment strategies
derived from a single patient cohort could not be replicated. As John Marshall says,
\The current challenge for sepsis research lies in a failure of concept and reluctance
to abandon a demonstrably ineectual research model" [Marshall, 2014]. Thus,
novel, eective and valid data-driven research models are needed to understand
pathomechanisms and maximize the benets from the existing treatments.
In this thesis, the rst clinico-transcriptomics approach was built to identify a
subset of patients that might benet from HC treatment in septic shock patients.
Serum ratio of IFN and IL-10 was found to be the best marker to make this
treatment decision. It was validated further on three independent datasets. High
ratio indicated better survival without HC treatment while a benet was observed
for low ratio when HC treatment was initiated. Clinical parameters and
transcriptomic evidence suggested that the patients with high ratio might be
`immunologically t' as these patients survived more often, and their transcriptome
reected the presence of greater extent of activated macrophages and T-cells.
Interestingly, the activation of macrophages and T-cells can be switched on in
patients with low ratios. This `switch' would be an interesting research to be
followed in the future with more precise immune assays. Currently, the concern
about side eects of HC such as infections in patients with less severe septic shock
has imposed more restrictive recommendations by the Surviving Sepsis Campaign.
Thus, HC application is only recommended for patients not responding to adequate
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uid resuscitation and vasopressor therapy [Dellinger et al., 2008, Dellinger et al.,
2013]. It seems intuitively promising to include an immune biomarker, such as
IFN/IL-10 reecting the status of the patients' immune system. If conrmed using
a randomized clinical trial, IFN/IL-10 can be a suitable theranostic marker to
guide HC therapy in septic shock patients.
The second clinico-transcriptomics approach was developed to understand the
sex-based pathomechanisms in the trauma patients. The ndings from this
approach were validated using another dataset of patients with burn injuries. The
approach included the statistical analysis pipeline that synchronized the time lapse
of the proles based on the temporal severity score of each patient. After critical
trauma, female and male patients showed distinct transcriptomic dierences that
might have worked in support of female patients. For example, a stronger innate
immune response at the very early phase of the disease may support early clearance
of the pathogen and its associated molecular patterns. Upregulation of wound
healing processes may explain reduced multiple organ failure during the acute
phase. Downregulated energy metabolism during the acute phase may make female
patients less susceptible to oxidative stress, and the upregulated adaptive immune
system reects an earlier recovery and rebuilding of the adaptive immunity that
may protect them from secondary infections. These results support our
understanding of the better clinical course in female patients after trauma and may
encourage investigations into gender-based medicine in the future.
Although the survival benets of pre-estrus females and sex-hormone
modulation in males have been successfully demonstrated in animal septic models
[Roll, 2015], there has not been any clinical trials testing the benets of the
sex-hormone modulation in septic patients. The transcriptomic evidence gathered in
this thesis argued that such modulation by the treatment of Flutamide or Atraric
acid might have enhanced the tolerance in the liver of septic male mice. Flutamide
is an FDA-approved drug currently being used in the treatment of prostate cancer
[Akaza, 2011]. Hence, if proven eective in the randomized clinical trial of septic
patients, Flutamide can serve as a therapy which is ready for adoption for the
treatment of septic patients, especially males.
The insights provided by the clinico-transcriptomics approaches may signicantly
contribute to improving the outcome in critically ill patients with cortico- and sex-
steroids.
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Appendix
Table A.1: Detailed inclusion criteria of CORTICUS, HSSG, SISPCT and the
Crossover study
Dataset Inclusion criteria
CORTICUS 1. Clinical evidence of infection within the previous 72 hours (may
be present longer than 72 hours), only one of a, b, c, or d required:
a) Presence of polymorphonuclear cells in a normally sterile
body uid (excluding blood);
b) Positive culture or Gram staining of blood, sputum, urine
or normal sterile body uid;
c) Focus of infection identied by visual inspection (e.g.
ruptured bowel with the presence of free air or bowel contents
in the abdomen found at the time of surgery, wound with
purulent drainage);
d) Other clinical evidence of infection - treated community
acquired pneumonia, purpura fulminans, necrotising fascitis,
etc.
2. Evidence of a systemic response to infection as dened by the
presence of two or more of the following signs within the previous
24 hours (these signs may be present longer than 72 hours):
a) Fever (temperature > 38.3C) or hypothermia (rectal
temperature < 35.6C);
b) Tachycardia (heart rate of > 90 beat/min);
c) Tachypnea (respiratory rate > 20 breaths/min, PaCO2 <
32 mmHg) or patient requires invasive mechanical ventilation;
d) Alteration of the WBC count: > 12,000 cells/mm3, < 4,000
cells/mm3 or > 10% immature neutrophils (bands).
3. Evidence of shock dened by (a and b both required within the
previous 72 hours (may NOT be present longer than 72 hours).
a) A systolic blood pressure < 90 mmHg or a decrease
in SBP of more than 50 mmHg from baseline in previous
hypertensive patients (for at least one hour) despite adequate
uid replacement OR need for vasopressors for at least one
hour (infusion of dopamine  5 mcg/kg/min or any dose of
adrenaline, noradrenaline, phenylephrine or vasopressin) to
maintain a SBP  90 mmHg;
b) Hypoperfusion or organ dysfunction which is not the result
of underlying diseases or drugs, but is attributable to sepsis,
including one of the following:
1. Sustained oliguria (urine output < 0.5 ml/kg/h for a
minimum of 1 hour)
2. Metabolic acidosis [pH of < 7.3, or a base decit of 
5.0 mmol/L, or an increased lactic acid concentration (> 2
mmol/L)].
Continued on next page
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Dataset Inclusion criteria
3. Arterial hypoxemia (PaO2/FiO2 < 280 in the absence
of pneumonia)(PaO2/FiO2 < 200 in the presence of
pneumonia).
4. Thrombocytopenia - platelet count  100,000 cells/mm3.
5. Acute altered mental status (Glasgow Coma Scale < 14
or acute change from baseline).
4. Age  18 years
5. Informed Consent
6. Measured cortisol level at baseline and 60 minutes after 0.25
mg cosyntropin stimulation
HSSG 1. Patients reclassied into infection and sepsis using the Sepsis-3
classication criteria [Singer et al., 2016, Giamarellos-Bourboulis
et al., 2017]
2. Age  18 years
3. Informed Consent
4. Community-acquired pneumonia and intraabdominal infections
SISPCT 1. Onset of severe sepsis (A and B both required) or septic
shock (C) < 24 h. Severe sepsis was dened as the presence of
microbiologically proven, clinically proven, or suspected infection;
presence of Systemic Inammatory Response Syndrome (A); and
development of at least one organ dysfunction (B) within the last
24 hours.
A) Diagnosis of SIRS required the fullment of at least two
of the following criteria: hypo- ( 36C) or hyperthermia (
38C), tachycardia ( 90 bpm); tachypnea ( 20 breaths/min)
and/or an arterial pCO2  4.3 kPa (32 mmHg) and/or
mechanical ventilation; leukocytosis  12000/l or leukopenia
 4000/l and/or a left shift in the dierential white blood
cell count  10%
B) For the diagnosis of organ dysfunction one of the following
criteria had to be fullled:
i. Presence of acute encephalopathy with reduced
vigilance, agitation, disorientation, delirium not explained
by psychotropic medication,
ii. Thrombocytopenia  100.000/l or a drop in the
thrombocyte count > 30% within 24 hours not explained
by hemorrhage,
iii. Arterial hypoxemia with an arterial pO2 < 10 kPa (75
mmHg) when breathing normally or an oxygenation index
(paO2/FiO2 33kPa (250 mmHg) not explained by presence
of a pulmonary or cardiac disease,
Continued on next page
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iv. Arterial hypotension with a systolic blood pressure  90
mmHg or mean arterial blood pressure  70 mmHg for at
least one hour despite adequate uid loading not explained
by other causes of shock,
v. Renal dysfunction with an urine output  0.5 ml/kg/h
for at least one hour despite adequate uid loading and/or
increase of serum creatinine more than twofold above the
reference range of the local laboratory,
vi. Metabolic acidosis with a base decit  5.0 mmol/l or
a serum lactate 1.5 fold above the reference range of the
local laboratory.
2. Age  18 years
3. Informed consent
Crossover 1. Presence of septic shock including,
a) Proven or strongly suspected infection
b) Three or more of these conditions: mechanical ventilation,
heart rate of more than 90 beats per minute, temperature of
more than 38C or less than 36C, a white blood cell count of
more than 12,000 cells/l or less than 4,000 cells/l, or more
than 10% immature cells
c) Sepsis-induced hypotension (systolic blood pressure of less
than 90 mmHg or a reduction of more than 40 mmHg from
baseline in the absence of other causes of hypotension)
2. Patients requiring norepinephrine to maintain a mean
arterial pressure of more than 70 mmHg despite adequate uid
resuscitation.
3. Age  18 years
4. Informed Consent
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Table A.2: Detailed exclusion criteria of CORTICUS, HSSG, SISPCT and the
Crossover study
Dataset Exclusion criteria
CORTICUS 1. Pregnancy,
2. Age less than 18,
3. Underlying disease with a prognosis for survival of less than 3
months,
4. Cardiopulmonary resuscitation within 72 hours before study,
5. Drug-induced immunosuppression, including chemotherapy or
radiation therapy within 4 weeks before the study,
6. Administration of chronic corticosteroids in the last 6 months
or acute steroid therapy (any dose) within 4 weeks (including
inhaled steroids). Topical steroids are not exclusions,
7. HIV positivity,
8. Presence of an advanced directive to withhold or withdraw life
sustaining treatment (i.e. DNR),
9. Advanced cancer with a life expectancy less than 3 months,
10. Acute myocardial infarction or pulmonary embolus,
11. Another experimental drug study within the last 30 days,
12. Moribund patients likely to die within 24 hours,
13. Patients in the ICU for more than 2 months at the time of
the start of septic shock,
HSSG 1. Infection by the human immunodeciency virus,
2. < 1,000 neutrophils/mm3
3. Systemic intake of more than 0.3mg/kg of equivalent
prednisolone the last 15 days
SISPCT 1. Pregnant or breast-feeding women,
2. Fertile female women without eective contraception,
3. Participation in interventional clinical trial within the last 30
days,
4. Current participation in any study,
5. Former participation in this trial,
6. Selenium intoxication,
7. No commitment to full patient support (i.e. DNR order),
8. Patient's death is considered imminent due to coexisting
disease,
Continued on next page
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9. Relationship of the patient to study team member (i.e.
colleague, relative),
10. Infection where guidelines recommend a longer duration of
antimicrobial therapy (i.e. endocarditis, tuberculosis, malaria
etc),
11. Immunocompromised patients.
Crossover 1. Pregnancy,
2. Glucocorticoid medication within the last 3 months,
3. Ongoing immunosuppressive therapy,
4. Hematologic diseases,
5. Moribund state.
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Figure A.1: Cluster of all gene sets being downregulated in female patients in at least two
phases among the early pre-acute, pre-acute and acute phase.
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Figure A.2: Cluster of all gene sets being upregulated in female patients in the early
pre-acute phase.
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Figure A.3: Cluster of all gene sets being upregulated in female patients in the late post-
acute phase.
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Figure A.4: Cluster of all gene sets being upregulated in female patients in the pre-acute
phase.
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Figure A.5: Cluster of all gene sets being upregulated in female patients during the acute
phase.
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Figure A.6: Cluster of all gene sets being downregulated in female patients during the
acute phase.
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Figure A.7: Cluster of all gene sets being upregulated in female patients in at least two
phases among the early pre-acute, pre-acute and acute phase.
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